{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 371046, "items": [{"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T09:17:25Z", "timestamp": 1574759845315}, "publisher-location": "Cham", "reference-count": 47, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319270142", "type": "print"}, {"value": "9783319270166", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27016-6_6", "type": "book-chapter", "created": {"date-parts": [[2016, 1, 25]], "date-time": "2016-01-25T08:08:54Z", "timestamp": 1453709334000}, "page": "107-120", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting"], "prefix": "10.1007", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 1, 26]]}, "reference": [{"key": "6_CR1", "doi-asserted-by": "publisher", "first-page": "4472", "DOI": "10.1200/JCO.2006.05.6382", "volume": "24", "author": "B Bloechl-Daum", "year": "2006", "unstructured": "Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478", "journal-title": "J Clin Oncol"}, {"key": "6_CR2", "doi-asserted-by": "publisher", "first-page": "249", "DOI": "10.1007/s40265-013-0019-1", "volume": "73", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249\u2013262", "journal-title": "Drugs"}, {"key": "6_CR3", "doi-asserted-by": "publisher", "first-page": "1281", "DOI": "10.1517/14656566.2013.799141", "volume": "14", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM (2013) The current status of the use of palonosetron. Expert Opin Pharmacother 14:1281\u20131284", "journal-title": "Expert Opin Pharmacother"}, {"key": "6_CR4", "doi-asserted-by": "publisher", "first-page": "450", "DOI": "10.1634/theoncologist.2014-0229", "volume": "20", "author": "M Aapro", "year": "2015", "unstructured": "Aapro M, Carides A, Rapoport BL (2015) Aprepitant and fosaprepitant: a ten-year review of efficacy and safety. Oncologist 20:450\u2013458", "journal-title": "Oncologist"}, {"key": "6_CR5", "first-page": "155", "volume": "9", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Dev Ther 9:155\u2013161", "journal-title": "Drug Des Dev Ther"}, {"key": "6_CR6", "doi-asserted-by": "publisher", "first-page": "1127", "DOI": "10.1586/14737140.2015.1088787", "volume": "15", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127\u20131133", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "6_CR7", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1016/j.suponc.2011.05.002", "volume": "9", "author": "RM Navari", "year": "2011", "unstructured": "Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195", "journal-title": "J Support Oncol"}, {"key": "6_CR8", "doi-asserted-by": "publisher", "first-page": "1655", "DOI": "10.1007/s00520-012-1710-6", "volume": "21", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663", "journal-title": "Support Care Cancer"}, {"key": "6_CR9", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/1756-9966-28-131", "volume": "28", "author": "L Tan", "year": "2009", "unstructured": "Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1\u20137", "journal-title": "J Exp Clin Cancer Res"}, {"key": "6_CR10", "doi-asserted-by": "publisher", "first-page": "20", "DOI": "10.1016/j.cmonc.2011.11.001", "volume": "9", "author": "RM Navari", "year": "2012", "unstructured": "Navari RM (2012) Treatment of chemotherapy-induced nausea. Community Oncol 9:20\u201326", "journal-title": "Community Oncol"}, {"key": "6_CR11", "author": "RM Stern", "year": "2011", "unstructured": "Stern RM, Koch KL, Andrews PLR (2011) Nausea: mechanisms and management. Oxford University Press, Oxford/New York", "volume-title": "Nausea: mechanisms and management"}, {"key": "6_CR12", "doi-asserted-by": "publisher", "first-page": "281", "DOI": "10.2165/00003495-199753020-00007", "volume": "53", "author": "B Fulton", "year": "1997", "unstructured": "Fulton B, Goa KL (1997) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281\u2013298", "journal-title": "Drugs"}, {"key": "6_CR13", "doi-asserted-by": "crossref", "first-page": "1325", "DOI": "10.1177/106002809703101110", "volume": "31", "author": "JC Kando", "year": "1997", "unstructured": "Kando JC, Shepski JC, Satterlee W, Patel JK, Rearns SG, Green AL (1997) Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother 31:1325\u20131334", "journal-title": "Ann Pharmacother"}, {"key": "6_CR14", "doi-asserted-by": "publisher", "first-page": "87", "DOI": "10.1016/0893-133X(94)00129-N", "volume": "14", "author": "FP Bymaster", "year": "1996", "unstructured": "Bymaster FP, Calligaro D, Falcone J, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396", "journal-title": "Neuropsychopharmacology"}, {"key": "6_CR15", "doi-asserted-by": "crossref", "first-page": "52", "DOI": "10.1192/S0007125000298115", "volume": "174", "author": "CME Stephenson", "year": "1999", "unstructured": "Stephenson CME, Pilowsky LS (1999) Psychopharmacology of olanzapine: a review. Br J Psychiatry 174:52\u201358", "journal-title": "Br J Psychiatry"}, {"key": "6_CR16", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1176/appi.psy.43.3.175", "volume": "43", "author": "W Breithart", "year": "2002", "unstructured": "Breithart W, Tremblay A, Gibson C (2002) An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 43:175\u2013182", "journal-title": "Psychosomatics"}, {"key": "6_CR17", "doi-asserted-by": "publisher", "first-page": "515", "DOI": "10.1046/j.1440-1819.2001.00898.x", "volume": "55", "author": "KS Kim", "year": "2001", "unstructured": "Kim KS, Pae CU, Chae JH, Bahk WM, Jun T (2001) An open pilot trial of olanzapine for delirium for the Korean population. Psychiatry Clin Neurosci 55:515\u2013519", "journal-title": "Psychiatry Clin Neurosci"}, {"key": "6_CR18", "doi-asserted-by": "publisher", "first-page": "546", "DOI": "10.1016/S0885-3924(02)00378-0", "volume": "23", "author": "N Khojainova", "year": "2002", "unstructured": "Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales GR (2002) Olanzapine in the management of cancer pain. J Pain Symptom Manage 23:546\u2013550", "journal-title": "J Pain Symptom Manage"}, {"key": "6_CR19", "doi-asserted-by": "publisher", "first-page": "341", "DOI": "10.1016/S0014-2999(01)01399-1", "volume": "430", "author": "FP Bymaster", "year": "2001", "unstructured": "Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW, Cohen ML (2001) Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 430:341\u2013349", "journal-title": "Eur J Pharmacol"}, {"key": "6_CR20", "doi-asserted-by": "publisher", "first-page": "79", "DOI": "10.1016/j.neulet.2005.08.062", "volume": "392", "author": "JA Rudd", "year": "2006", "unstructured": "Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PL, Sanger GJ (2006) Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392:79\u201383", "journal-title": "Neurosci Lett"}, {"key": "6_CR21", "doi-asserted-by": "publisher", "first-page": "3773", "DOI": "10.1210/en.2010-0061", "volume": "151", "author": "K Yakabi", "year": "2010", "unstructured": "Yakabi K, Sadakane C, Noguchi M, Ohno S, Shoki R, Chinen K, Aoyanna T, Sakurada T, Takabayashi H, Hattori T (2010) Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology 151:3773\u20133782", "journal-title": "Endocrinology"}, {"key": "6_CR22", "doi-asserted-by": "publisher", "first-page": "2029", "DOI": "10.2146/ajhp100638", "volume": "68", "author": "KM Hurren", "year": "2011", "unstructured": "Hurren KM, Berlie HD (2011) Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm 68:2029\u20132037", "journal-title": "Am J Health Syst Pharm"}, {"key": "6_CR23", "first-page": "22", "volume": "62", "author": "DB Allison", "year": "2001", "unstructured": "Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 62:22\u201331", "journal-title": "J Clin Psychiatry"}, {"key": "6_CR24", "first-page": "443", "volume": "58", "author": "AS Hale", "year": "1997", "unstructured": "Hale AS (1997) Olanzapine. Br J Hosp Med 58:443\u2013445", "journal-title": "Br J Hosp Med"}, {"key": "6_CR25", "doi-asserted-by": "publisher", "first-page": "438", "DOI": "10.1016/S0033-3182(99)71210-7", "volume": "40", "author": "LE Goldstein", "year": "1999", "unstructured": "Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438\u2013443", "journal-title": "Psychosomatics"}, {"key": "6_CR26", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1089/109662103764978506", "volume": "6", "author": "WC Jackson", "year": "2003", "unstructured": "Jackson WC, Tavernier L (2003) Olanzapine for intractable nausea in palliative care patients. J Palliat Med 6:251\u2013255", "journal-title": "J Palliat Med"}, {"key": "6_CR27", "doi-asserted-by": "publisher", "first-page": "432", "DOI": "10.1177/1049909110369532", "volume": "27", "author": "N Licup", "year": "2010", "unstructured": "Licup N, Baumrucker S (2010) Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 27:432\u2013434", "journal-title": "Am J Hosp Palliat Care"}, {"key": "6_CR28", "doi-asserted-by": "publisher", "first-page": "485", "DOI": "10.1016/S0885-3924(03)00078-2", "volume": "25", "author": "SD Passik", "year": "2003", "unstructured": "Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D, Beaver M, Comparet J, Brown J (2003) A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 25:485\u2013489", "journal-title": "J Pain Symptom Manage"}, {"key": "6_CR29", "doi-asserted-by": "publisher", "first-page": "526", "DOI": "10.1016/S0885-3924(02)00391-3", "volume": "23", "author": "SD Passik", "year": "2002", "unstructured": "Passik SD, Lundberg J, Kirsh KL, Theobald D, Donagby K, Holtschaw E, Cooper M, Dugan W (2002) Clinical note: a pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced pain and cancer. J Pain Symptom Manage 23:526\u2013532", "journal-title": "J Pain Symptom Manage"}, {"key": "6_CR30", "doi-asserted-by": "publisher", "first-page": "84", "DOI": "10.1002/(SICI)1099-1611(200001/02)9:1<84::AID-PON440>3.0.CO;2-T", "volume": "9", "author": "WF Pirl", "year": "2000", "unstructured": "Pirl WF, Roth AJ (2000) Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 9:84\u201387", "journal-title": "Psychooncology"}, {"key": "6_CR31", "doi-asserted-by": "publisher", "first-page": "578", "DOI": "10.1016/S0885-3924(03)00143-X", "volume": "25", "author": "M Srivastava", "year": "2003", "unstructured": "Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 25:578\u2013582", "journal-title": "J Pain Symptom Manage"}, {"key": "6_CR32", "first-page": "35", "volume": "20", "author": "JC Lundberg", "year": "2000", "unstructured": "Lundberg JC, Passik S (2000) Controlling opioid-induced nausea with olanzapine. Prim Care Cancer 20:35\u201337", "journal-title": "Prim Care Cancer"}, {"key": "6_CR33", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1081/CNV-200029066", "volume": "22", "author": "S Passik", "year": "2004", "unstructured": "Passik S, Navari RM, Jung SH, Nagy CK, Vinson J, Kirsh KL, Loehrer PJ (2004) A phase I trial of olanzapine for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest 22:383\u2013388", "journal-title": "Cancer Invest"}, {"key": "6_CR34", "doi-asserted-by": "publisher", "first-page": "529", "DOI": "10.1007/s00520-004-0755-6", "volume": "13", "author": "RM Navari", "year": "2005", "unstructured": "Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 13:529\u2013534", "journal-title": "Support Care Cancer"}, {"key": "6_CR35", "doi-asserted-by": "publisher", "first-page": "1285", "DOI": "10.1007/s00520-007-0248-5", "volume": "15", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285\u20131291", "journal-title": "Support Care Cancer"}, {"key": "6_CR36", "doi-asserted-by": "publisher", "first-page": "542", "DOI": "10.1016/j.jpainsymman.2013.05.003", "volume": "47", "author": "N Mizukami", "year": "2014", "unstructured": "Mizukami N, Yamanchi M, Koike K et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 47:542\u2013550", "journal-title": "J Pain Symptom Manage"}, {"issue": "29_suppl", "key": "6_CR37", "doi-asserted-by": "crossref", "first-page": "176", "DOI": "10.1200/jco.2015.33.29_suppl.176", "volume": "33", "author": "Rudolph M. Navari", "year": "2015", "unstructured": "Navari RM, Qin R, Ruddy KJ et al (2015) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): alliance: A221301, a randomized, double-blind, placebo-controlled trial. ASCO palliative care symposium, abstract 176, Boston", "journal-title": "Journal of Clinical Oncology"}, {"key": "6_CR38", "doi-asserted-by": "publisher", "first-page": "678", "DOI": "10.1002/cncr.22823", "volume": "110", "author": "YC Tina Shih", "year": "2007", "unstructured": "Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678\u2013685", "journal-title": "Cancer"}, {"key": "6_CR39", "doi-asserted-by": "publisher", "first-page": "232", "DOI": "10.1093/annonc/mdq194", "volume": "21", "author": "F Roila", "year": "2010", "unstructured": "Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano A, Morrow G, Oliver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:232\u2013243", "journal-title": "Ann Oncol"}, {"key": "6_CR40", "doi-asserted-by": "publisher", "first-page": "4189", "DOI": "10.1200/JCO.2010.34.4614", "volume": "29", "author": "E Basch", "year": "2011", "unstructured": "Basch E, Prestrud AA, Hesketh PJ, Kris MG, Fever PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freunlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198", "journal-title": "J Clin Oncol"}, {"key": "6_CR41", "doi-asserted-by": "publisher", "first-page": "4077", "DOI": "10.1200/JCO.2003.07.968", "volume": "21", "author": "MC Kris", "year": "2003", "unstructured": "Kris MC (2003) Why do we need another antiemetic? Just ask. J Clin Oncol 21:4077\u20134080", "journal-title": "J Clin Oncol"}, {"key": "6_CR42", "doi-asserted-by": "crossref", "first-page": "51", "DOI": "10.6004/jnccn.2007.0007", "volume": "5", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM (2007) Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 5:51\u201359", "journal-title": "J Natl Compr Canc Netw"}, {"key": "6_CR43", "doi-asserted-by": "publisher", "first-page": "1293", "DOI": "10.1007/s00520-007-0255-6", "volume": "15", "author": "LH Einhorn", "year": "2007", "unstructured": "Einhorn LH, Brames ML, Dreicer R, Nichols CR, Cullen MT, Bubalo J (2007) Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293\u20131300", "journal-title": "Support Care Cancer"}, {"key": "6_CR44", "doi-asserted-by": "publisher", "first-page": "3998", "DOI": "10.1200/JCO.2011.39.5558", "volume": "30", "author": "C Albany", "year": "2012", "unstructured": "Albany C, Brames ML, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 antagonist plus dexamethasone in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol 30:3998\u20134003", "journal-title": "J Clin Oncol"}, {"key": "6_CR45", "unstructured": "NCCN Clinical Practice Guidelines in Oncology version 1 2015. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from url: \n                http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf\n                \n              . Accessed 30 Sept 2015"}, {"key": "6_CR46", "unstructured": "Generic cost of olanzapine. \n                www.goodrx.com\n                \n              . Accessed Oct 2015"}, {"key": "6_CR47", "unstructured": "Editor, Wholesale cost of fosaprepitant (2015) Med Lett 57:60", "DOI": "10.1016/j.psyneuen.2015.04.025", "doi-asserted-by": "crossref"}], "container-title": ["Management of Chemotherapy-Induced Nausea and Vomiting"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27016-6_6", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T11:31:35Z", "timestamp": 1559388695000}, "score": 73.80926, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319270142", "9783319270166"], "references-count": 47, "URL": "http://dx.doi.org/10.1007/978-3-319-27016-6_6", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T09:17:25Z", "timestamp": 1574759845528}, "publisher-location": "Cham", "reference-count": 53, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319270142", "type": "print"}, {"value": "9783319270166", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27016-6_10", "type": "book-chapter", "created": {"date-parts": [[2016, 1, 25]], "date-time": "2016-01-25T08:08:54Z", "timestamp": 1453709334000}, "page": "163-176", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Treatment of Chemotherapy-Induced Nausea"], "prefix": "10.1007", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 1, 26]]}, "reference": [{"key": "10_CR1", "doi-asserted-by": "publisher", "first-page": "4472", "DOI": "10.1200/JCO.2006.05.6382", "volume": "24", "author": "B Bloechl-Daum", "year": "2006", "unstructured": "Bloechl-Daum B, Deuson RR, Panagiotis M et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478", "journal-title": "J Clin Oncol"}, {"key": "10_CR2", "doi-asserted-by": "publisher", "first-page": "515", "DOI": "10.2165/00003495-200969050-00002", "volume": "69", "author": "RM Navari", "year": "2009", "unstructured": "Navari RM (2009) Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69:515\u2013533", "journal-title": "Drugs"}, {"key": "10_CR3", "doi-asserted-by": "publisher", "first-page": "1073", "DOI": "10.2217/fon.10.74", "volume": "6", "author": "RM Navari", "year": "2010", "unstructured": "Navari RM (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 6:1073\u20131084", "journal-title": "Future Oncol"}, {"key": "10_CR4", "doi-asserted-by": "publisher", "first-page": "1853", "DOI": "10.2165/11203680-000000000-00000", "volume": "69", "author": "MP Curran", "year": "2009", "unstructured": "Curran MP, Robinson DM (2009) Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 69:1853\u20131858", "journal-title": "Drugs"}, {"key": "10_CR5", "doi-asserted-by": "publisher", "first-page": "1607", "DOI": "10.1517/17425250903451675", "volume": "12", "author": "KK Sankhala", "year": "2009", "unstructured": "Sankhala KK, Pandya DM, Sarantopoulos J et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607\u20131614", "journal-title": "Expert Opin Drug Metab Toxicol"}, {"key": "10_CR6", "first-page": "155", "volume": "9", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV. Drug Des Dev Ther 9:155\u2013161", "journal-title": "Drug Des Dev Ther"}, {"key": "10_CR7", "doi-asserted-by": "publisher", "first-page": "1127", "DOI": "10.1586/14737140.2015.1088787", "volume": "15", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127\u20131133", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "10_CR8", "doi-asserted-by": "publisher", "first-page": "529", "DOI": "10.1007/s00520-004-0755-6", "volume": "13", "author": "RM Navari", "year": "2005", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 13:529\u2013534", "journal-title": "Support Care Cancer"}, {"key": "10_CR9", "doi-asserted-by": "publisher", "first-page": "1285", "DOI": "10.1007/s00520-007-0248-5", "volume": "15", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285\u20131291", "journal-title": "Support Care Cancer"}, {"key": "10_CR10", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/1756-9966-28-131", "volume": "28", "author": "L Tan", "year": "2009", "unstructured": "Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1\u20137", "journal-title": "J Exp Clin Cancer Res"}, {"key": "10_CR11", "author": "RM Stern", "year": "2011", "unstructured": "Stern RM, Koch KL, Andrews PLR (2011) Nausea: mechanisms and management. Oxford University Press, New York", "volume-title": "Nausea: mechanisms and management"}, {"key": "10_CR12", "doi-asserted-by": "publisher", "first-page": "1297", "DOI": "10.2165/00003495-200059060-00008", "volume": "59", "author": "K Simpson", "year": "2000", "unstructured": "Simpson K, Spencer CM, McClellan KJ (2000) Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 59:1297\u20131315", "journal-title": "Drugs"}, {"key": "10_CR13", "first-page": "477", "volume": "23", "author": "E Kimura", "year": "1996", "unstructured": "Kimura E, Niimi E, Wantabe A et al (1996) Study on the clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 23:477\u2013481", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "10_CR14", "first-page": "1163", "volume": "26", "author": "T Taguchi", "year": "1999", "unstructured": "Taguchi T, Tsukamoto F, Watanabe T et al (1999) Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 26:1163\u20131170", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "10_CR15", "unstructured": "Dolasetron drug alert. WHO Drug Information, 40, No. 3 (2006)"}, {"key": "10_CR16", "unstructured": "U.S. Food and Drug Information. FDA drug safety communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Available from URL: \n                http://www.fda.gov/Drugs.DrugSafety/usm237081.htm\n                \n              . Accessed 27 Dec 2010"}, {"issue": "2", "key": "10_CR17", "doi-asserted-by": "publisher", "first-page": "104", "DOI": "10.1007/s00520-004-0700-8", "volume": "13", "author": "F Roila", "year": "2005", "unstructured": "Roila F, Warr D, Clark-Snow R et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):104\u2013108", "journal-title": "Support Care Cancer"}, {"key": "10_CR18", "doi-asserted-by": "publisher", "first-page": "1289", "DOI": "10.1200/JCO.2005.04.022", "volume": "23", "author": "O Geling", "year": "2005", "unstructured": "Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289\u20131294", "journal-title": "J Clin Oncol"}, {"key": "10_CR19", "doi-asserted-by": "publisher", "first-page": "765", "DOI": "10.1016/S1470-2045(05)70325-9", "volume": "6", "author": "JT Hickok", "year": "2005", "unstructured": "Hickok JT, Roscoe JA, Morrow GR et al (2005) 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 6:765\u2013772", "journal-title": "Lancet Oncol"}, {"key": "10_CR20", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1016/S1470-2045(08)70313-9", "volume": "10", "author": "M Saito", "year": "2009", "unstructured": "Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol 10:115\u2013124", "journal-title": "Lancet Oncol"}, {"key": "10_CR21", "doi-asserted-by": "publisher", "first-page": "2822", "DOI": "10.1200/JCO.2005.09.050", "volume": "23", "author": "DG Warr", "year": "2005", "unstructured": "Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822\u20132830", "journal-title": "J Clin Oncol"}, {"key": "10_CR22", "doi-asserted-by": "publisher", "first-page": "354", "DOI": "10.1007/s00520-005-0914-4", "volume": "14", "author": "PJ Hesketh", "year": "2006", "unstructured": "Hesketh PJ, Grunberg SM, Herrstedt J et al (2006) Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354\u2013360", "journal-title": "Support Care Cancer"}, {"key": "10_CR23", "doi-asserted-by": "publisher", "first-page": "1278", "DOI": "10.1016/j.ejca.2005.01.024", "volume": "41", "author": "DG Warr", "year": "2005", "unstructured": "Warr DG, Grunberg SM, Gralla RJ et al (2005) The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer 41:1278\u20131285", "journal-title": "Eur J Cancer"}, {"key": "10_CR24", "first-page": "408", "volume": "4", "author": "T Grote", "year": "2006", "unstructured": "Grote T, Hajdenberg Cartnell A et al (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4:408", "journal-title": "J Support Oncol"}, {"key": "10_CR25", "doi-asserted-by": "publisher", "first-page": "1217", "DOI": "10.1007/s00520-010-0941-7", "volume": "19", "author": "L Celio", "year": "2011", "unstructured": "Celio L, Frustaci S, Denaro A et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi-center, phase III trial. Support Care Cancer 19:1217\u20131225", "journal-title": "Support Care Cancer"}, {"key": "10_CR26", "doi-asserted-by": "publisher", "first-page": "1441", "DOI": "10.1093/annonc/mdl137", "volume": "17", "author": "MS Aapro", "year": "2006", "unstructured": "Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441\u20131449", "journal-title": "Ann Oncol"}, {"key": "10_CR27", "unstructured": "Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the control of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol (in press)", "DOI": "10.1016/j.suponc.2011.05.002", "doi-asserted-by": "crossref"}, {"key": "10_CR28", "unstructured": "Cruz FM, de Iracema Gomes Cubero D, Taranto P (2011) Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer (in press)", "DOI": "10.1007/s00520-011-1138-4", "doi-asserted-by": "crossref"}, {"key": "10_CR29", "doi-asserted-by": "publisher", "first-page": "533", "DOI": "10.1185/030079907X167525", "volume": "23", "author": "E Meiri", "year": "2007", "unstructured": "Meiri E, Jhangiani H, Vredenburgh JJ et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23:533\u2013543", "journal-title": "Curr Med Res Opin"}, {"key": "10_CR30", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1093/annonc/mdh047", "volume": "15", "author": "P Eisenberg", "year": "2004", "unstructured": "Eisenberg P, MacKintosh FR, Ritch P et al (2004) Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 15:330\u2013337", "journal-title": "Ann Oncol"}, {"key": "10_CR31", "first-page": "193", "volume": "626", "author": "C Rojas", "year": "2010", "unstructured": "Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. J Pharmacol 626:193\u2013199", "journal-title": "J Pharmacol"}, {"key": "10_CR32", "doi-asserted-by": "publisher", "first-page": "2473", "DOI": "10.1002/cncr.11817", "volume": "98", "author": "P Eisenberg", "year": "2003", "unstructured": "Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 98:2473\u20132482", "journal-title": "Cancer"}, {"key": "10_CR33", "doi-asserted-by": "publisher", "first-page": "1570", "DOI": "10.1093/annonc/mdg417", "volume": "14", "author": "R Gralla", "year": "2003", "unstructured": "Gralla R, Lichinitser M, Van der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase II trial comparing single dose of palonosetron with ondansetron. Ann Oncol 14:1570\u20131577", "journal-title": "Ann Oncol"}, {"key": "10_CR34", "unstructured": "Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198", "DOI": "10.1200/JCO.2010.34.4614", "doi-asserted-by": "crossref"}, {"key": "10_CR35", "unstructured": "NCCN National Comprehensive Cancer Network (2015) Antiemesis: Clinical Practice Guidelines in Oncology. v 1. \n                www.nccn.org"}, {"issue": "Suppl 5", "key": "10_CR36", "doi-asserted-by": "publisher", "first-page": "232", "DOI": "10.1093/annonc/mdq194", "volume": "21", "author": "F Roila", "year": "2010", "unstructured": "Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):232\u2013243", "journal-title": "Ann Oncol"}, {"key": "10_CR37", "first-page": "89", "volume": "1", "author": "RM Navari", "year": "2003", "unstructured": "Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 1:89\u2013103", "journal-title": "J Support Oncol"}, {"key": "10_CR38", "doi-asserted-by": "publisher", "first-page": "1011", "DOI": "10.1038/sj.bjc.6603048", "volume": "94", "author": "J Vardy", "year": "1999", "unstructured": "Vardy J, Chiew KS, Gallica J et al (1999) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011\u20131015", "journal-title": "Br J Cancer"}, {"key": "10_CR39", "doi-asserted-by": "publisher", "first-page": "1083", "DOI": "10.1093/annonc/mdp584", "volume": "21", "author": "M Aapro", "year": "2010", "unstructured": "Aapro M, Fabi A, Nole F et al (2010) Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083\u20131088", "journal-title": "Ann Oncol"}, {"key": "10_CR40", "doi-asserted-by": "publisher", "first-page": "87", "DOI": "10.1016/0893-133X(94)00129-N", "volume": "14", "author": "FP Bymaster", "year": "1996", "unstructured": "Bymaster FP, Calligaro D, Falcone J et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396", "journal-title": "Neuropsychopharmacology"}, {"key": "10_CR41", "doi-asserted-by": "publisher", "first-page": "341", "DOI": "10.1016/S0014-2999(01)01399-1", "volume": "430", "author": "FP Bymaster", "year": "2001", "unstructured": "Bymaster FP, Falcone JF, Bauzon D et al (2001) Potent antagonism of 5HT3 and 5HT6 receptors by olanzapine. Eur J Pharmacol 430:341\u2013349", "journal-title": "Eur J Pharmacol"}, {"key": "10_CR42", "first-page": "22", "volume": "62", "author": "DB Allison", "year": "2001", "unstructured": "Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 62:22\u201331", "journal-title": "J Clin Psychiatry"}, {"key": "10_CR43", "first-page": "443", "volume": "58", "author": "AS Hale", "year": "1997", "unstructured": "Hale AS (1997) Olanzapine. Br J Hosp Med 58:443\u2013445", "journal-title": "Br J Hosp Med"}, {"key": "10_CR44", "doi-asserted-by": "publisher", "first-page": "438", "DOI": "10.1016/S0033-3182(99)71210-7", "volume": "40", "author": "LE Goldstein", "year": "1999", "unstructured": "Goldstein LE, Sporn J, Brown S et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438\u2013443", "journal-title": "Psychosomatics"}, {"issue": "3", "key": "10_CR45", "doi-asserted-by": "publisher", "first-page": "185", "DOI": "10.1097/AJP.0b013e3181934276", "volume": "25", "author": "G Irving", "year": "2009", "unstructured": "Irving G, Jensen M, Cramer M et al (2009) Efficacy and tolerability of gastric-retentive gabapentin for the treatment of post-herpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 25(3):185\u2013192", "journal-title": "Clin J Pain"}, {"key": "10_CR46", "doi-asserted-by": "publisher", "first-page": "1703", "DOI": "10.1016/S0140-6736(03)13365-X", "volume": "361", "author": "T Guttuso", "year": "2003", "unstructured": "Guttuso T, Roscoe J, Griggs J (2003) Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 361:1703\u20131705", "journal-title": "Lancet"}, {"key": "10_CR47", "doi-asserted-by": "publisher", "first-page": "G566", "DOI": "10.1152/ajpgi.00113.2003", "volume": "285", "author": "MD Sickle Van", "year": "2003", "unstructured": "Van Sickle MD, Oland LD, Mackie K et al (2003) Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285:G566\u2013G576", "journal-title": "Am J Physiol Gastrointest Liver Physiol"}, {"key": "10_CR48", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1016/S0091-3057(01)00531-7", "volume": "69", "author": "NA Darmani", "year": "2001", "unstructured": "Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav 69:239\u2013249", "journal-title": "Pharmacol Biochem Behav"}, {"issue": "1", "key": "10_CR49", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1517/13543784.17.1.85", "volume": "17", "author": "MP Davis", "year": "2008", "unstructured": "Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17(1):85\u201395", "journal-title": "Expert Opin Investig Drugs"}, {"key": "10_CR50", "author": "S Mills", "year": "2000", "unstructured": "Mills S, Bone K (2000) Principles and practice of phytotherapy. Churchill Livingstone, Oxford", "volume-title": "Principles and practice of phytotherapy"}, {"key": "10_CR51", "doi-asserted-by": "publisher", "first-page": "234", "DOI": "10.1002/pbc.22778", "volume": "56", "author": "AK Pillai", "year": "2011", "unstructured": "Pillai AK, Sharma KK, Gupta YK, Bakhshi S (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 56:234\u2013238", "journal-title": "Pediatr Blood Cancer"}, {"key": "10_CR52", "doi-asserted-by": "publisher", "first-page": "563", "DOI": "10.1007/s00520-008-0528-8", "volume": "17", "author": "SM Zick", "year": "2009", "unstructured": "Zick SM, Ruffin MT, Normolle DP et al (2009) Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 17:563\u2013572", "journal-title": "Support Care Cancer"}, {"key": "10_CR53", "unstructured": "Ryan JL, Heckler C, Dakhil SR et al (2009) Ginger for chemotherapy-related nausea in cancer patients: a URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients. J Clin Oncol 27(15s):abstract 9511"}], "container-title": ["Management of Chemotherapy-Induced Nausea and Vomiting"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27016-6_10", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T11:25:46Z", "timestamp": 1559388346000}, "score": 70.414154, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319270142", "9783319270166"], "references-count": 53, "URL": "http://dx.doi.org/10.1007/978-3-319-27016-6_10", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T09:17:25Z", "timestamp": 1574759845415}, "publisher-location": "Cham", "reference-count": 20, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319270142", "type": "print"}, {"value": "9783319270166", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27016-6_9", "type": "book-chapter", "created": {"date-parts": [[2016, 1, 25]], "date-time": "2016-01-25T08:08:54Z", "timestamp": 1453709334000}, "page": "157-162", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Clinical Management of CINV"], "prefix": "10.1007", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 1, 26]]}, "reference": [{"issue": "5", "key": "9_CR1", "doi-asserted-by": "publisher", "first-page": "232", "DOI": "10.1093/annonc/mdq194", "volume": "21", "author": "F Roila", "year": "2010", "unstructured": "Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):232\u2013243", "journal-title": "Ann Oncol"}, {"key": "9_CR2", "doi-asserted-by": "publisher", "first-page": "4189", "DOI": "10.1200/JCO.2010.34.4614", "volume": "29", "author": "E Basch", "year": "2011", "unstructured": "Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198", "journal-title": "J Clin Oncol"}, {"key": "9_CR3", "unstructured": "NCCN Clinical Practice Guidelines in Oncology version 1 2012. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: \n                http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf\n                \n              . Accessed 30 Sept 2015"}, {"key": "9_CR4", "doi-asserted-by": "publisher", "first-page": "2932", "DOI": "10.1200/JCO.2006.06.9591", "volume": "24", "author": "MG Kris", "year": "2006", "unstructured": "Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932\u20132947", "journal-title": "J Clin Oncol"}, {"key": "9_CR5", "first-page": "89", "volume": "1", "author": "RM Navari", "year": "2003", "unstructured": "Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 1:89\u2013103", "journal-title": "J Support Oncol"}, {"key": "9_CR6", "doi-asserted-by": "publisher", "first-page": "1289", "DOI": "10.1200/JCO.2005.04.022", "volume": "23", "author": "O Geling", "year": "2005", "unstructured": "Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289\u20131294", "journal-title": "J Clin Oncol"}, {"key": "9_CR7", "doi-asserted-by": "publisher", "first-page": "765", "DOI": "10.1016/S1470-2045(05)70325-9", "volume": "6", "author": "JT Hickok", "year": "2005", "unstructured": "Hickok JT, Roscoe JA, Morrow GR et al (2005) 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 6:765\u2013772", "journal-title": "Lancet Oncol"}, {"key": "9_CR8", "doi-asserted-by": "publisher", "first-page": "1655", "DOI": "10.1007/s00520-012-1710-6", "volume": "21", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663", "journal-title": "Support Care Cancer"}, {"key": "9_CR9", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1016/j.suponc.2011.05.002", "volume": "9", "author": "RM Navari", "year": "2011", "unstructured": "Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195", "journal-title": "J Support Oncol"}, {"issue": "4", "key": "9_CR10", "doi-asserted-by": "publisher", "first-page": "423", "DOI": "10.1007/s00520-009-0680-9", "volume": "18", "author": "BL Rapoport", "year": "2010", "unstructured": "Rapoport BL, Jordon K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423\u2013431", "journal-title": "Support Care Cancer"}, {"key": "9_CR11", "first-page": "155", "volume": "9", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Dev Ther 9:155\u2013161", "journal-title": "Drug Des Dev Ther"}, {"key": "9_CR12", "doi-asserted-by": "publisher", "first-page": "1127", "DOI": "10.1586/14737140.2015.1088787", "volume": "15", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127\u20131133", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "9_CR13", "doi-asserted-by": "crossref", "first-page": "51", "DOI": "10.6004/jnccn.2007.0007", "volume": "5", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM (2007) Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 5:51\u201359", "journal-title": "J Natl Compr Canc Netw"}, {"key": "9_CR14", "doi-asserted-by": "publisher", "first-page": "1293", "DOI": "10.1007/s00520-007-0255-6", "volume": "15", "author": "LH Einhorn", "year": "2007", "unstructured": "Einhorn LH, Brames ML, Dreicer R et al (2007) Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293\u20131300", "journal-title": "Support Care Cancer"}, {"key": "9_CR15", "doi-asserted-by": "publisher", "first-page": "3998", "DOI": "10.1200/JCO.2011.39.5558", "volume": "30", "author": "C Albany", "year": "2012", "unstructured": "Albany C, Brames ML, Fausel C et al (2012) Randomized, double-blind, placebo-controlled, phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 antagonist plus dexamethasone in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol 30:3998\u20134003", "journal-title": "J Clin Oncol"}, {"key": "9_CR16", "doi-asserted-by": "publisher", "first-page": "49", "DOI": "10.1016/j.bbmt.2012.07.019", "volume": "19", "author": "PJ Stiff", "year": "2013", "unstructured": "Stiff PJ, Fox-German MP, Kiley K et al (2013) Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19:49\u201355", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "9_CR17", "doi-asserted-by": "publisher", "first-page": "784", "DOI": "10.1038/bmt.2010.205", "volume": "46", "author": "K Jordan", "year": "2011", "unstructured": "Jordan K, Jahn F, Jahn P et al (2011) The NK-1 receptor antagonist aprepitant in high-dose chemotherapy (high dose melphalan and high dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transpl 46:784\u2013789", "journal-title": "Bone Marrow Transpl"}, {"key": "9_CR18", "doi-asserted-by": "publisher", "first-page": "20", "DOI": "10.1016/j.cmonc.2011.11.001", "volume": "9", "author": "RM Navari", "year": "2012", "unstructured": "Navari RM (2012) Treatment of chemotherapy-induced nausea. Community Oncol 9:20\u201326", "journal-title": "Community Oncol"}, {"key": "9_CR19", "doi-asserted-by": "publisher", "first-page": "1285", "DOI": "10.1007/s00520-007-0248-5", "volume": "15", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285\u20131291", "journal-title": "Support Care Cancer"}, {"key": "9_CR20", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/1756-9966-28-131", "volume": "28", "author": "L Tan", "year": "2009", "unstructured": "Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1\u20137", "journal-title": "J Exp Clin Cancer Res"}], "container-title": ["Management of Chemotherapy-Induced Nausea and Vomiting"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27016-6_9", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T11:25:34Z", "timestamp": 1559388334000}, "score": 68.22961, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319270142", "9783319270166"], "references-count": 20, "URL": "http://dx.doi.org/10.1007/978-3-319-27016-6_9", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T09:17:24Z", "timestamp": 1574759844792}, "publisher-location": "Cham", "reference-count": 0, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319270142", "type": "print"}, {"value": "9783319270166", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27016-6_12", "type": "book-chapter", "created": {"date-parts": [[2016, 1, 25]], "date-time": "2016-01-25T08:08:54Z", "timestamp": 1453709334000}, "page": "179-181", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Future Directions"], "prefix": "10.1007", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 1, 26]]}, "container-title": ["Management of Chemotherapy-Induced Nausea and Vomiting"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27016-6_12", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 1, 25]], "date-time": "2016-01-25T08:09:02Z", "timestamp": 1453709342000}, "score": 66.821175, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319270142", "9783319270166"], "references-count": 0, "URL": "http://dx.doi.org/10.1007/978-3-319-27016-6_12"}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T09:17:25Z", "timestamp": 1574759845078}, "publisher-location": "Cham", "reference-count": 16, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319270142", "type": "print"}, {"value": "9783319270166", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27016-6_1", "type": "book-chapter", "created": {"date-parts": [[2016, 1, 25]], "date-time": "2016-01-25T08:08:54Z", "timestamp": 1453709334000}, "page": "1-3", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Introduction"], "prefix": "10.1007", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 1, 26]]}, "reference": [{"key": "1_CR1", "doi-asserted-by": "publisher", "first-page": "4472", "DOI": "10.1200/JCO.2006.05.6382", "volume": "24", "author": "B Bloechl-Daum", "year": "2006", "unstructured": "Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "1_CR2", "doi-asserted-by": "publisher", "first-page": "497", "DOI": "10.1007/s00520-006-0173-z", "volume": "15", "author": "L Cohen", "year": "2007", "unstructured": "Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503", "journal-title": "Support Care Cancer"}, {"key": "1_CR3", "doi-asserted-by": "publisher", "first-page": "515", "DOI": "10.2165/00003495-200969050-00002", "volume": "69", "author": "RM Navari", "year": "2009", "unstructured": "Navari RM (2009) Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69:515\u2013533", "journal-title": "Drugs"}, {"key": "1_CR4", "doi-asserted-by": "publisher", "first-page": "1074", "DOI": "10.2217/fon.10.74", "volume": "6", "author": "RM Navari", "year": "2010", "unstructured": "Navari RM (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 6:1074\u20131084", "journal-title": "Future Oncol"}, {"key": "1_CR5", "doi-asserted-by": "publisher", "first-page": "1853", "DOI": "10.2165/11203680-000000000-00000", "volume": "69", "author": "MP Curran", "year": "2009", "unstructured": "Curran MP, Robinson DM (2009) Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 69:1853\u20131858", "journal-title": "Drugs"}, {"key": "1_CR6", "doi-asserted-by": "publisher", "first-page": "1607", "DOI": "10.1517/17425250903451675", "volume": "12", "author": "KK Sankhala", "year": "2009", "unstructured": "Sankhala KK, Pandya DM, Sarantopoulos J et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607\u20131614", "journal-title": "Expert Opin Drug Metab Toxicol"}, {"key": "1_CR7", "first-page": "155", "volume": "9", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Dev Ther 9:155\u2013161", "journal-title": "Drug Des Dev Ther"}, {"key": "1_CR8", "doi-asserted-by": "publisher", "first-page": "1127", "DOI": "10.1586/14737140.2015.1088787", "volume": "15", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127\u20131133", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "1_CR9", "doi-asserted-by": "publisher", "first-page": "1285", "DOI": "10.1007/s00520-007-0248-5", "volume": "15", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285\u20131291", "journal-title": "Support Care Cancer"}, {"key": "1_CR10", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/1756-9966-28-131", "volume": "28", "author": "L Tan", "year": "2009", "unstructured": "Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1\u20137", "journal-title": "J Exp Clin Cancer Res"}, {"key": "1_CR11", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1016/j.suponc.2011.05.002", "volume": "9", "author": "RM Navari", "year": "2011", "unstructured": "Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195", "journal-title": "J Support Oncol"}, {"key": "1_CR12", "doi-asserted-by": "publisher", "first-page": "20", "DOI": "10.1016/j.cmonc.2011.11.001", "volume": "9", "author": "RM Navari", "year": "2012", "unstructured": "Navari RM (2012) Treatment of chemotherapy-induced nausea. Community Oncol 9:20\u201326", "journal-title": "Community Oncol"}, {"key": "1_CR13", "year": "2011", "unstructured": "Stern RM, Koch KL, Andrews PLR (eds) (2011) Nausea: mechanisms and management. Oxford University Press, New York", "volume-title": "Nausea: mechanisms and management"}, {"issue": "5", "key": "1_CR14", "doi-asserted-by": "publisher", "first-page": "232", "DOI": "10.1093/annonc/mdq194", "volume": "21", "author": "F Roila", "year": "2010", "unstructured": "Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):232\u2013243", "journal-title": "Ann Oncol"}, {"key": "1_CR15", "doi-asserted-by": "publisher", "first-page": "4189", "DOI": "10.1200/JCO.2010.34.4614", "volume": "29", "author": "E Basch", "year": "2011", "unstructured": "Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198", "journal-title": "J Clin Oncol"}, {"key": "1_CR16", "unstructured": "NCCN Clinical Practice Guidelines in Oncology version 1 2015. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: \n                http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf\n                \n              . Accessed Oct 2015"}], "container-title": ["Management of Chemotherapy-Induced Nausea and Vomiting"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27016-6_1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T11:34:00Z", "timestamp": 1559388840000}, "score": 66.821175, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319270142", "9783319270166"], "references-count": 16, "URL": "http://dx.doi.org/10.1007/978-3-319-27016-6_1", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T09:17:25Z", "timestamp": 1574759845393}, "publisher-location": "Cham", "reference-count": 0, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319270142", "type": "print"}, {"value": "9783319270166", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27016-6_11", "type": "book-chapter", "created": {"date-parts": [[2016, 1, 25]], "date-time": "2016-01-25T08:08:54Z", "timestamp": 1453709334000}, "page": "177-178", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Conclusions"], "prefix": "10.1007", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 1, 26]]}, "container-title": ["Management of Chemotherapy-Induced Nausea and Vomiting"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27016-6_11", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 1, 25]], "date-time": "2016-01-25T08:09:01Z", "timestamp": 1453709341000}, "score": 66.821175, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319270142", "9783319270166"], "references-count": 0, "URL": "http://dx.doi.org/10.1007/978-3-319-27016-6_11"}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T02:09:24Z", "timestamp": 1574302164717}, "reference-count": 88, "publisher": "Springer Science and Business Media LLC", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drugs"], "published-print": {"date-parts": [[2009]]}, "DOI": "10.2165/00003495-200969050-00002", "type": "journal-article", "created": {"date-parts": [[2009, 5, 21]], "date-time": "2009-05-21T22:05:38Z", "timestamp": 1242943538000}, "page": "515-533", "source": "Crossref", "is-referenced-by-count": 57, "title": ["Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting"], "prefix": "10.1007", "volume": "69", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"issue": "5", "key": "R2-2-20090521", "doi-asserted-by": "crossref", "first-page": "497", "DOI": "10.1007/s00520-006-0173-z", "volume": "15", "author": "Cohen", "year": "2007", "journal-title": "Support Care Cancer"}, {"key": "R3-2-20090521", "author": "Bloechl-Daum", "volume": "24", "first-page": "4472", "year": "2006", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2006.05.6382", "doi-asserted-by": "crossref"}, {"key": "R4-2-20090521", "author": "Gralla", "volume": "104", "first-page": "864", "year": "2005", "journal-title": "Cancer", "DOI": "10.1002/cncr.21222", "doi-asserted-by": "crossref"}, {"issue": "Suppl. 1", "key": "R5-2-20090521", "first-page": "3", "volume": "4", "author": "Schwartzberg", "year": "2006", "journal-title": "J Support Oncol"}, {"key": "R6-2-20090521", "author": "Grunberg", "volume": "13", "first-page": "80", "year": "2005", "journal-title": "Support Care Cancer", "DOI": "10.1007/s00520-004-0718-y", "doi-asserted-by": "crossref"}, {"key": "R7-2", "author": "Guyton", "year": "2006"}, {"key": "R8-2-20090521", "author": "Baker", "volume": "28", "first-page": "469", "year": "2005", "journal-title": "Gastroenterol Nurs", "DOI": "10.1097/00001610-200511000-00003", "doi-asserted-by": "crossref"}, {"key": "R9-2-20090521", "author": "Koga", "volume": "14", "first-page": "366", "year": "1992", "journal-title": "Neurosci Res", "DOI": "10.1016/0168-0102(92)90078-Q", "doi-asserted-by": "crossref"}, {"key": "R10-2-20090521", "author": "Yates", "volume": "267", "first-page": "R974", "year": "1994", "journal-title": "Am J Physiol"}, {"issue": "Suppl.", "key": "R11-2-20090521", "first-page": "3", "volume": "4", "author": "Navari", "year": "2007", "journal-title": "Commun Oncol"}, {"key": "R12-2-20090521", "author": "Roila", "volume": "17", "first-page": "20", "year": "2006", "journal-title": "Ann Oncol"}, {"key": "R13-2-20090521", "author": "Kris", "volume": "24", "first-page": "2932", "year": "2006", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2006.06.9591", "doi-asserted-by": "crossref"}, {"key": "R14-2-20090521", "author": "Hesketh", "volume": "14", "first-page": "2242", "year": "1996", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1996.14.8.2242", "doi-asserted-by": "crossref"}, {"key": "R15-2-20090521", "author": "Navari", "volume": "13", "first-page": "1242", "year": "1995", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1995.13.5.1242", "doi-asserted-by": "crossref"}, {"key": "R16-2-20090521", "author": "Navari", "volume": "12", "first-page": "2204", "year": "1994", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1994.12.10.2204", "doi-asserted-by": "crossref"}, {"key": "R17-2-20090521", "author": "Perez", "volume": "13", "first-page": "1036", "year": "1995", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1995.13.4.1036", "doi-asserted-by": "crossref"}, {"key": "R18-2", "author": "Sanger", "first-page": "207", "year": "1992"}, {"issue": "2", "key": "R19-2-20090521", "doi-asserted-by": "crossref", "first-page": "104", "DOI": "10.1007/s00520-004-0700-8", "volume": "13", "author": "Roila", "year": "2005", "journal-title": "Support Care Cancer"}, {"key": "R20-2-20090521", "author": "Latreille", "volume": "16", "first-page": "1174", "year": "1998", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1998.16.3.1174", "doi-asserted-by": "crossref"}, {"key": "R21-2-20090521", "author": "Navari", "volume": "13", "first-page": "2408", "year": "1995", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1995.13.9.2408", "doi-asserted-by": "crossref"}, {"key": "R22-2-20090521", "volume": "342", "first-page": "1554", "year": "2000", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJM200005253422102", "doi-asserted-by": "crossref"}, {"key": "R23-2-20090521", "author": "Geling", "volume": "23", "first-page": "1289", "year": "2005", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2005.04.022", "doi-asserted-by": "crossref"}, {"key": "R24-2-20090521", "author": "Hickok", "volume": "6", "first-page": "765", "year": "2005", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(05)70325-9", "doi-asserted-by": "crossref"}, {"key": "R25-2-20090521", "author": "Rudd", "volume": "33", "first-page": "1607", "year": "1994", "journal-title": "Neuropharmacology", "DOI": "10.1016/0028-3908(94)90136-8", "doi-asserted-by": "crossref"}, {"key": "R26-2", "author": "Andrews", "first-page": "255", "year": "1994"}, {"key": "R27-2-20090521", "author": "Hesketh", "volume": "12", "first-page": "550", "year": "2004", "journal-title": "Support Care Cancer"}, {"key": "R28-2-20090521", "author": "Mantovani", "volume": "77", "first-page": "941", "year": "1996", "journal-title": "Cancer", "DOI": "10.1002/(SICI)1097-0142(19960301)77:5<941::AID-CNCR21>3.0.CO;2-2", "doi-asserted-by": "crossref"}, {"key": "R29-2-20090521", "author": "Navari", "volume": "1", "first-page": "89", "year": "2003", "journal-title": "J Support Oncol"}, {"key": "R30-2-20090521", "author": "Simpson", "volume": "59", "first-page": "1297", "year": "2000", "journal-title": "Drugs", "DOI": "10.2165/00003495-200059060-00008", "doi-asserted-by": "crossref"}, {"key": "R31-2-20090521", "author": "Kimura", "volume": "23", "first-page": "477", "year": "1996", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "R32-2-20090521", "author": "Taguchi", "volume": "26", "first-page": "1163", "year": "1999", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "R33-2-20090521", "author": "Hesketh", "volume": "18", "first-page": "163", "year": "2000", "journal-title": "Cancer Invest", "DOI": "10.3109/07357900009038248", "doi-asserted-by": "crossref"}, {"key": "R34-2-20090521", "author": "Perez", "volume": "5", "first-page": "31", "year": "1997", "journal-title": "Support Care Cancer", "DOI": "10.1007/BF01681959", "doi-asserted-by": "crossref"}, {"key": "R35-2-20090521", "author": "Navari", "volume": "37", "first-page": "1276", "year": "2003", "journal-title": "Ann Pharmacother", "DOI": "10.1345/aph.1C510", "doi-asserted-by": "crossref"}, {"key": "R36-2-20090521", "author": "Hickok", "volume": "97", "first-page": "2880", "year": "2003", "journal-title": "Cancer", "DOI": "10.1002/cncr.11408", "doi-asserted-by": "crossref"}, {"key": "R37-2-20090521", "author": "Eisenberg", "volume": "98", "first-page": "2473", "year": "2003", "journal-title": "Cancer", "DOI": "10.1002/cncr.11817", "doi-asserted-by": "crossref"}, {"key": "R38-2-20090521", "author": "Gralla", "volume": "14", "first-page": "1570", "year": "2003", "journal-title": "Ann Oncol", "DOI": "10.1093/annonc/mdg417", "doi-asserted-by": "crossref"}, {"key": "R39-2-20090521", "author": "Aapro", "volume": "17", "first-page": "1441", "year": "2006", "journal-title": "Ann Oncol", "DOI": "10.1093/annonc/mdl137", "doi-asserted-by": "crossref"}, {"key": "R41-2-20090521", "author": "Kris", "volume": "21", "first-page": "4077", "year": "2003", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2003.07.968", "doi-asserted-by": "crossref"}, {"key": "R42-2-20090521", "author": "Diemunsch", "volume": "60", "first-page": "533", "year": "2000", "journal-title": "Drugs", "DOI": "10.2165/00003495-200060030-00002", "doi-asserted-by": "crossref"}, {"key": "R43-2-20090521", "author": "Fasth", "volume": "40", "first-page": "665", "year": "1997", "journal-title": "J Labeled Comp Radiopharm"}, {"key": "R44-2-20090521", "author": "Tattersall", "volume": "35", "first-page": "1121", "year": "1996", "journal-title": "Neuropharmacology", "DOI": "10.1016/S0028-3908(96)00020-2", "doi-asserted-by": "crossref"}, {"key": "R45-2-20090521", "author": "Minami", "volume": "363", "first-page": "49", "year": "1998", "journal-title": "Eur J Pharmacol", "DOI": "10.1016/S0014-2999(98)00784-5", "doi-asserted-by": "crossref"}, {"key": "R46-2-20090521", "author": "Minami", "volume": "428", "first-page": "215", "year": "2001", "journal-title": "Eur J Pharmacol", "DOI": "10.1016/S0014-2999(01)01297-3", "doi-asserted-by": "crossref"}, {"key": "R47-2-20090521", "author": "Tattersall", "volume": "39", "first-page": "652", "year": "2000", "journal-title": "Neuropharmacology", "DOI": "10.1016/S0028-3908(99)00172-0", "doi-asserted-by": "crossref"}, {"key": "R48-2-20090521", "author": "Kris", "volume": "89", "first-page": "817", "year": "1997", "journal-title": "J Natl Cancer Inst", "DOI": "10.1093/jnci/89.11.817", "doi-asserted-by": "crossref"}, {"key": "R49-2-20090521", "author": "Hesketh", "volume": "17", "first-page": "338", "year": "1999", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1999.17.1.338", "doi-asserted-by": "crossref"}, {"key": "R50-2-20090521", "author": "Navari", "volume": "340", "first-page": "190", "year": "1999", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJM199901213400304", "doi-asserted-by": "crossref"}, {"key": "R51-2-20090521", "author": "Cocquyt", "volume": "37", "first-page": "835", "year": "2001", "journal-title": "Eur J Cancer", "DOI": "10.1016/S0959-8049(00)00416-0", "doi-asserted-by": "crossref"}, {"key": "R52-2-20090521", "author": "Campos", "volume": "19", "first-page": "1759", "year": "2001", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2001.19.6.1759", "doi-asserted-by": "crossref"}, {"key": "R53-2-20090521", "author": "Van Belle", "volume": "94", "first-page": "3032", "year": "2002", "journal-title": "Cancer", "DOI": "10.1002/cncr.10516", "doi-asserted-by": "crossref"}, {"key": "R54-2-20090521", "author": "Chawla", "volume": "97", "first-page": "2290", "year": "2003", "journal-title": "Cancer", "DOI": "10.1002/cncr.11320", "doi-asserted-by": "crossref"}, {"key": "R55-2-20090521", "author": "Hesketh", "volume": "21", "first-page": "4112", "year": "2003", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2003.01.095", "doi-asserted-by": "crossref"}, {"key": "R56-2-20090521", "author": "Poli-Bigelli", "volume": "97", "first-page": "3090", "year": "2003", "journal-title": "Cancer", "DOI": "10.1002/cncr.11433", "doi-asserted-by": "crossref"}, {"key": "R57-2-20090521", "author": "De Wit", "volume": "21", "first-page": "4105", "year": "2003", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2003.10.128", "doi-asserted-by": "crossref"}, {"issue": "6", "key": "R58-2-20090521", "doi-asserted-by": "crossref", "first-page": "1000", "DOI": "10.1093/annonc/mdl019", "volume": "17", "author": "Schmoll", "year": "2006", "journal-title": "Ann Oncol"}, {"key": "R59-2-20090521", "author": "Warr", "volume": "23", "first-page": "2822", "year": "2005", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2005.09.050", "doi-asserted-by": "crossref"}, {"key": "R60-2-20090521", "author": "Navari", "volume": "9", "first-page": "774", "year": "2008", "journal-title": "Curr Opin Investig Drugs"}, {"key": "R61-2-20090521", "author": "De Wit", "volume": "40", "first-page": "403", "year": "2004", "journal-title": "Eur J Cancer", "DOI": "10.1016/j.ejca.2003.08.028", "doi-asserted-by": "crossref"}, {"issue": "5", "key": "R62-2-20090521", "doi-asserted-by": "crossref", "first-page": "715", "DOI": "10.1586/14737140.4.5.715", "volume": "4", "author": "Navari", "year": "2004", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "R63-2-20090521", "author": "Dando", "volume": "64", "first-page": "777", "year": "2004", "journal-title": "Drugs", "DOI": "10.2165/00003495-200464070-00013", "doi-asserted-by": "crossref"}, {"key": "R64-2-20090521", "author": "Navari", "volume": "16", "first-page": "1977", "year": "2007", "journal-title": "Expert Opin Investig Drugs", "DOI": "10.1517/13543784.16.12.1977", "doi-asserted-by": "crossref"}, {"key": "R65-2-20090521", "author": "Lasseter", "volume": "47", "first-page": "834", "year": "2007", "journal-title": "J Clin Pharmacol", "DOI": "10.1177/0091270007301800", "doi-asserted-by": "crossref"}, {"key": "R72-2-20090521", "author": "Hesketh", "volume": "12", "first-page": "596", "year": "1994", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1994.12.3.596", "doi-asserted-by": "crossref"}, {"key": "R73-2-20090521", "volume": "332", "first-page": "1", "year": "1995", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJM199501053320101", "doi-asserted-by": "crossref"}, {"key": "R74-2-20090521", "author": "Latreille", "volume": "3", "first-page": "307", "year": "1995", "journal-title": "Support Care Cancer", "DOI": "10.1007/BF00335307", "doi-asserted-by": "crossref"}, {"key": "R75-2-20090521", "author": "Ioannidis", "volume": "18", "first-page": "3409", "year": "2000", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2000.18.19.3409", "doi-asserted-by": "crossref"}, {"key": "R76-2-20090521", "volume": "16", "first-page": "2937", "year": "1998", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1998.16.9.2937", "doi-asserted-by": "crossref"}, {"key": "R77-2-20090521", "volume": "22", "first-page": "725", "year": "2004", "journal-title": "J Clin Oncol", "DOI": "10.1200/jco.2004.22.14_suppl.725", "doi-asserted-by": "crossref"}, {"key": "R78-2-20090521", "author": "Bymaster", "volume": "14", "first-page": "87", "year": "1996", "journal-title": "Neuropsychopharmacology", "DOI": "10.1016/0893-133X(94)00129-N", "doi-asserted-by": "crossref"}, {"key": "R79-2-20090521", "author": "Bymaster", "volume": "430", "first-page": "341", "year": "2001", "journal-title": "Eur J Pharmacol", "DOI": "10.1016/S0014-2999(01)01399-1", "doi-asserted-by": "crossref"}, {"key": "R80-2-20090521", "author": "Allison", "volume": "62", "first-page": "22", "year": "2001", "journal-title": "J Clin Psychiatry"}, {"key": "R81-2-20090521", "author": "Hale", "volume": "58", "first-page": "443", "year": "1997", "journal-title": "Br J Hosp Med"}, {"key": "R82-2-20090521", "author": "Goldstein", "volume": "40", "first-page": "438", "year": "1999", "journal-title": "Psychosomatics", "DOI": "10.1016/S0033-3182(99)71210-7", "doi-asserted-by": "crossref"}, {"key": "R83-2-20090521", "author": "Passik", "volume": "22", "first-page": "383", "year": "2004", "journal-title": "Cancer Invest", "DOI": "10.1081/CNV-200029066", "doi-asserted-by": "crossref"}, {"key": "R84-2-20090521", "author": "Navari", "volume": "13", "first-page": "529", "year": "2005", "journal-title": "Support Care Cancer", "DOI": "10.1007/s00520-004-0755-6", "doi-asserted-by": "crossref"}, {"key": "R85-2-20090521", "author": "Cleeland", "volume": "89", "first-page": "1634", "year": "2000", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V", "doi-asserted-by": "crossref"}, {"key": "R86-2-20090521", "author": "Navari", "volume": "15", "first-page": "1285", "year": "2007", "journal-title": "Support Care Cancer", "DOI": "10.1007/s00520-007-0248-5", "doi-asserted-by": "crossref"}, {"key": "R87-2-20090521", "author": "Guttuso", "volume": "361", "first-page": "1703", "year": "2003", "journal-title": "Lancet", "DOI": "10.1016/S0140-6736(03)13365-X", "doi-asserted-by": "crossref"}, {"key": "R88-2-20090521", "author": "Van Sickle", "volume": "310", "first-page": "329", "year": "2005", "journal-title": "Science", "DOI": "10.1126/science.1115740", "doi-asserted-by": "crossref"}, {"key": "R89-2-20090521", "author": "Martin", "volume": "2", "first-page": "305", "year": "2004", "journal-title": "J Support Oncol"}, {"issue": "Suppl.", "key": "R90-2-20090521", "first-page": "1", "volume": "5", "author": "Slatin", "year": "2007", "journal-title": "J Support Oncol"}, {"key": "R91-2-20090521", "author": "Koeller", "volume": "10", "first-page": "517", "year": "2002", "journal-title": "Support Care Cancer", "DOI": "10.1007/s00520-001-0335-y", "doi-asserted-by": "crossref"}, {"key": "R92-2-20090521", "author": "Navari", "volume": "5", "first-page": "51", "year": "2007", "journal-title": "J Natl Compr Canc Netw", "DOI": "10.6004/jnccn.2007.0007", "doi-asserted-by": "crossref"}, {"key": "R93-2-20090521", "author": "Einhorn", "volume": "15", "first-page": "1293", "year": "2007", "journal-title": "Support Care Cancer", "DOI": "10.1007/s00520-007-0255-6", "doi-asserted-by": "crossref"}, {"key": "R94-2-20090521", "author": "Fabi", "volume": "16", "first-page": "1375", "year": "2008", "journal-title": "Support Care Cancer", "DOI": "10.1007/s00520-008-0438-9", "doi-asserted-by": "crossref"}, {"key": "R95-2-20090521", "author": "Grunberg", "volume": "100", "first-page": "2261", "year": "2004", "journal-title": "Cancer", "DOI": "10.1002/cncr.20230", "doi-asserted-by": "crossref"}, {"key": "R96-2-20090521", "author": "Fabi", "volume": "11", "first-page": "156", "year": "2003", "journal-title": "Support Care Cancer"}], "container-title": ["Drugs"], "language": "en", "deposited": {"date-parts": [[2019, 2, 20]], "date-time": "2019-02-20T13:25:05Z", "timestamp": 1550669105000}, "score": 62.902588, "subtitle": ["Focus on Recent Developments"], "issued": {"date-parts": [[2009]]}, "references-count": 88, "journal-issue": {"issue": "5"}, "URL": "http://dx.doi.org/10.2165/00003495-200969050-00002", "relation": {"cites": []}, "ISSN": ["0012-6667"], "issn-type": [{"value": "0012-6667", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T13:26:39Z", "timestamp": 1574774799023}, "reference-count": 48, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 4, 21]], "date-time": "2017-04-21T00:00:00Z", "timestamp": 1492732800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Pediatr Drugs"], "published-print": {"date-parts": [[2017, 6]]}, "DOI": "10.1007/s40272-017-0228-2", "type": "journal-article", "created": {"date-parts": [[2017, 4, 21]], "date-time": "2017-04-21T13:41:52Z", "timestamp": 1492782112000}, "page": "213-222", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients"], "prefix": "10.1007", "volume": "19", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 4, 21]]}, "reference": [{"key": "228_CR1", "doi-asserted-by": "crossref", "first-page": "1356", "DOI": "10.1056/NEJMra1515442", "volume": "374", "author": "RM Navari", "year": "2016", "unstructured": "Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356\u201367.", "journal-title": "N Engl J Med"}, {"key": "228_CR2", "doi-asserted-by": "crossref", "first-page": "249", "DOI": "10.1007/s40265-013-0019-1", "volume": "73", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on new agents and new uses for older agents. Drugs. 2013;73:249\u201362.", "journal-title": "Drugs"}, {"key": "228_CR3", "doi-asserted-by": "crossref", "first-page": "191", "DOI": "10.1002/pbc.23114", "volume": "57", "author": "LL Dupuis", "year": "2011", "unstructured": "Dupuis LL, Boodhan Sung, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57:191\u20138.", "journal-title": "Pediatr Blood Cancer"}, {"key": "228_CR4", "doi-asserted-by": "crossref", "first-page": "323", "DOI": "10.1007/s00520-016-3384-y", "volume": "25", "author": "LL Dupuis", "year": "2017", "unstructured": "Dupuis LL, Sung L, Moassiotis A, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of chemotherapy-induced nausea and vomiting in children. Support Care Cancer. 2017;25:323\u201331.", "journal-title": "Support Care Cancer"}, {"key": "228_CR5", "doi-asserted-by": "crossref", "first-page": "537", "DOI": "10.1007/s00520-010-0994-7", "volume": "19", "author": "K Jordan", "year": "2011", "unstructured": "Jordan K, Roila F, Molassiotis A, et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer. 2011;19:537\u201342.", "journal-title": "Support Care Cancer"}, {"key": "228_CR6", "doi-asserted-by": "crossref", "first-page": "1073", "DOI": "10.1002/pbc.24508", "volume": "60", "author": "LL Dupuis", "year": "2013", "unstructured": "Dupuis LL, Boodham S, Holdsworth M et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medications in pediatric cancer patients. Pediatr Blood Cancer 2013;60:1073-82.", "journal-title": "Pediatr Blood Cancer"}, {"key": "228_CR7", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.1016/j.cmonc.2011.11.001", "volume": "9", "author": "RM Navari", "year": "2012", "unstructured": "Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol. 2012;9:20\u20136.", "journal-title": "Community Oncol"}, {"key": "228_CR8", "doi-asserted-by": "crossref", "first-page": "134", "DOI": "10.1056/NEJMoa1515725", "volume": "375", "author": "RM Navari", "year": "2016", "unstructured": "Navari RM, Qin R, Ruddy RJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134\u201342.", "journal-title": "N Engl J Med"}, {"key": "228_CR9", "year": "2011", "unstructured": "Stern RM, Koch KL, Andrews PLR, editors. Nausea: mechanisms and management. New York: Oxford University Press; 2011.", "volume-title": "Nausea: mechanisms and management"}, {"key": "228_CR10", "doi-asserted-by": "crossref", "first-page": "509", "DOI": "10.1007/s40264-016-0398-9", "volume": "39", "author": "M Lau Moon Lin", "year": "2016", "unstructured": "Lau Moon Lin M, Robinson PD, Flank J, et al. The safety of prochlorperazine in children: a systematic review and meta-analysis. Drug Saf. 2016;39:509\u201316.", "journal-title": "Drug Saf"}, {"key": "228_CR11", "doi-asserted-by": "crossref", "first-page": "1297", "DOI": "10.2165/00003495-200059060-00008", "volume": "59", "author": "K Simpson", "year": "2000", "unstructured": "Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2000;59:1297\u2013315.", "journal-title": "Drugs"}, {"key": "228_CR12", "first-page": "477", "volume": "23", "author": "E Kimura", "year": "1996", "unstructured": "Kimura E, Niimi E, Watanabe A, et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho. 1996;23:477\u201381.", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "228_CR13", "first-page": "1163", "volume": "26", "author": "T Taguchi", "year": "1999", "unstructured": "Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho. 1999;26:1163\u201370.", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "228_CR14", "doi-asserted-by": "crossref", "first-page": "163", "DOI": "10.3109/07357900009038248", "volume": "18", "author": "PJ Hesketh", "year": "2000", "unstructured": "Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18:163\u201373.", "journal-title": "Cancer Invest."}, {"key": "228_CR15", "first-page": "CD007786", "volume": "2", "author": "RS Phillips", "year": "2016", "unstructured": "Phillips RS, Friend AJ, Gibson F, et al. Antiemetic medication for the prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2016;2:CD007786.", "journal-title": "Cochrane Database Syst Rev"}, {"issue": "3", "key": "228_CR16", "first-page": "185", "volume": "20", "author": "World Health Organization", "year": "2006", "unstructured": "World Health Organization. Dolasetron mesylate and serious cardiovascular reactions. WHO Drug Information. 2006;20(3):185.", "journal-title": "WHO Drug Information"}, {"key": "228_CR17", "unstructured": "US Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with use of anzemet (dolasetron mesylate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020623s009lbl.pdf . Accessed 21 Mar 2017."}, {"key": "228_CR18", "unstructured": "Ondansetron: New Dose Restrictions. Prescriber Update 33(3):21. September 2012. http://www.medsafe.govt.nz/profs/PUArticles/OndansetronSept2012.htm . Accessed 23 Mar 2017."}, {"key": "228_CR19", "doi-asserted-by": "crossref", "first-page": "19", "DOI": "10.1016/j.annemergmed.2013.10.026", "volume": "64", "author": "SB Freedman", "year": "2014", "unstructured": "Freedman SB, Uleryk E, Rumantir M, et al. Ondansetron and the risk of cardiac arrhythmias: a systematic review and post marketing analysis. Ann Emerg Med. 2014;64:19\u201325.", "journal-title": "Ann Emerg Med"}, {"key": "228_CR20", "doi-asserted-by": "crossref", "first-page": "500", "DOI": "10.2146/ajhp130394", "volume": "71", "author": "YC Yeh", "year": "2014", "unstructured": "Yeh YC, Blouin GC, Reddy P. Evidence to support use of palonosetron over generic serotonin type-3 receptor antagonists for chemotherapy-induced nausea and vomiting. Am J Health Syst Pharm. 2014;71:500\u20136.", "journal-title": "Am J Health Syst Pharm"}, {"key": "228_CR21", "doi-asserted-by": "crossref", "first-page": "1281", "DOI": "10.1517/14656566.2013.799141", "volume": "14", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013;14:1281\u20134.", "journal-title": "Expert Opin Pharmacother"}, {"key": "228_CR22", "doi-asserted-by": "crossref", "first-page": "2599", "DOI": "10.1517/14656566.2014.972366", "volume": "15", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2015;15:2599\u2013608.", "journal-title": "Expert Opin Pharmacother"}, {"key": "228_CR23", "doi-asserted-by": "crossref", "first-page": "193", "DOI": "10.1016/j.ejphar.2009.10.002", "volume": "626", "author": "C Rojas", "year": "2010", "unstructured": "Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626:193\u20139.", "journal-title": "Eur J Pharmacol"}, {"key": "228_CR24", "doi-asserted-by": "crossref", "first-page": "332", "DOI": "10.1016/S1470-2045(15)00520-3", "volume": "17", "author": "G Kovacs", "year": "2016", "unstructured": "Kovacs G, Wachtel AE, Basharova EV, et al. Palonosetron versus ondansetron for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomized, phase 3, double blind, double dummy, non-inferiority study. Lancet Oncol. 2016;17:332\u201344.", "journal-title": "Lancet Oncol"}, {"key": "228_CR25", "doi-asserted-by": "crossref", "first-page": "675", "DOI": "10.1007/s40264-016-0418-9", "volume": "39", "author": "M Lau Moon Lin", "year": "2016", "unstructured": "Lau Moon Lin M, Robinson PD, Flank J, et al. The safety of metoclopramide in children: a systematic review and meta-analysis. Drug Saf. 2016;39:675\u201387.", "journal-title": "Drug Saf"}, {"key": "228_CR26", "unstructured": "European Medicine Agency. Metoclopramide use recommendations. London: EMA; 26 July 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/ . Accessed 23 Mar 2017."}, {"key": "228_CR27", "doi-asserted-by": "crossref", "first-page": "1144", "DOI": "10.1002/pbc.25955", "volume": "63", "author": "J Flank", "year": "2016", "unstructured": "Flank J, Robinson PD, Holdsworth M, et al. Guidelines for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer. 2016;63:1144\u201351.", "journal-title": "Pediatr Blood Cancer"}, {"key": "228_CR28", "doi-asserted-by": "crossref", "first-page": "3229", "DOI": "10.1007/s00520-015-2714-9", "volume": "23", "author": "S Bakhshi", "year": "2015", "unstructured": "Bakhshi S, Batra A, Biswas B, et al. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2015;23:3229\u201337.", "journal-title": "Support Care Cancer"}, {"key": "228_CR29", "doi-asserted-by": "crossref", "first-page": "585", "DOI": "10.1016/S1470-2045(15)00367-8", "volume": "16", "author": "HJ Kang", "year": "2015", "unstructured": "Kang HJ, Loftus S, Taylor A, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomized, double-blind, phase 3 trial. Lancet Oncol. 2015;16:585\u201394.", "journal-title": "Lancet Oncol"}, {"key": "228_CR30", "doi-asserted-by": "crossref", "first-page": "1977", "DOI": "10.1517/13543784.16.12.1977", "volume": "16", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007;16:1977\u201385.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "228_CR31", "doi-asserted-by": "crossref", "first-page": "1495", "DOI": "10.1200/JCO.2010.31.7859", "volume": "29", "author": "S Grunberg", "year": "2011", "unstructured": "Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2014EASE. J Clin Oncol. 2011;29:1495\u2013501.", "journal-title": "J Clin Oncol"}, {"key": "228_CR32", "first-page": "127", "volume": "19", "author": "A Shillingburg", "year": "2014", "unstructured": "Shillingburg A, Biondo L. Aprepitant and fosaprepitant use in children and adolescence at an academic medical center. J Pediatr Pharmacol Ther. 2014;19:127\u201331.", "journal-title": "J Pediatr Pharmacol Ther"}, {"key": "228_CR33", "doi-asserted-by": "crossref", "first-page": "450", "DOI": "10.1634/theoncologist.2014-0229", "volume": "20", "author": "M Aapro", "year": "2015", "unstructured": "Aapro M, Carides A, Rapoport BL, et al. Aprepitant and fosaprepitant: a 10\u00a0year review of efficacy and safety. Oncologist. 2015;20:450\u20138.", "journal-title": "Oncologist"}, {"key": "228_CR34", "first-page": "155", "volume": "9", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM. Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015;9:155\u201361.", "journal-title": "Drug Des Devel Ther"}, {"key": "228_CR35", "doi-asserted-by": "crossref", "first-page": "1127", "DOI": "10.1586/14737140.2015.1088787", "volume": "15", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2015;15:1127\u201333.", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "228_CR36", "doi-asserted-by": "crossref", "first-page": "281", "DOI": "10.2165/00003495-199753020-00007", "volume": "53", "author": "B Fulton", "year": "1997", "unstructured": "Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281\u201398.", "journal-title": "Drugs"}, {"key": "228_CR37", "doi-asserted-by": "crossref", "first-page": "87", "DOI": "10.1016/0893-133X(94)00129-N", "volume": "14", "author": "FP Bymaster", "year": "1996", "unstructured": "Bymaster FP, Calligaro D, Falcone J. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87\u201396.", "journal-title": "Neuropsychopharmacology"}, {"key": "228_CR38", "doi-asserted-by": "crossref", "first-page": "52", "DOI": "10.1192/S0007125000298115", "volume": "174", "author": "CME Stephenson", "year": "1999", "unstructured": "Stephenson CME, Pilowsky LS. Psychopharmacology of olanzapine: a review. Br J Psychiatry. 1999;174:52\u20138.", "journal-title": "Br J Psychiatry"}, {"key": "228_CR39", "doi-asserted-by": "crossref", "first-page": "175", "DOI": "10.1176/appi.psy.43.3.175", "volume": "43", "author": "W Breithart", "year": "2002", "unstructured": "Breithart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002;43:175\u201382.", "journal-title": "Psychosomatics"}, {"key": "228_CR40", "doi-asserted-by": "crossref", "first-page": "341", "DOI": "10.1016/S0014-2999(01)01399-1", "volume": "430", "author": "FP Bymaster", "year": "2001", "unstructured": "Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT (3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001;430:341\u20139.", "journal-title": "Eur J Pharmacol"}, {"key": "228_CR41", "doi-asserted-by": "crossref", "first-page": "79", "DOI": "10.1016/j.neulet.2005.08.062", "volume": "392", "author": "JA Rudd", "year": "2006", "unstructured": "Rudd JA, Ngan MP, Wai MK, et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett. 2006;392:79\u201383.", "journal-title": "Neurosci Lett"}, {"key": "228_CR42", "doi-asserted-by": "crossref", "first-page": "3773", "DOI": "10.1210/en.2010-0061", "volume": "151", "author": "K Yakabi", "year": "2010", "unstructured": "Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010;151:3773\u201382.", "journal-title": "Endocrinology"}, {"key": "228_CR43", "doi-asserted-by": "crossref", "first-page": "2029", "DOI": "10.2146/ajhp100638", "volume": "68", "author": "KM Hurren", "year": "2011", "unstructured": "Hurren KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm. 2011;68:2029\u201337.", "journal-title": "Am J Health Syst Pharm"}, {"key": "228_CR44", "first-page": "22", "volume": "62", "author": "DB Allison", "year": "2001", "unstructured": "Allison DB, Casey DE. Antipsychotic-associated weight gain: A review of the literature. J Clin Psychiatry. 2001;62:22\u201331.", "journal-title": "J Clin Psychiatry"}, {"key": "228_CR45", "first-page": "443", "volume": "58", "author": "AS Hale", "year": "1997", "unstructured": "Hale AS. Olanzapine. Br J Hosp Med. 1997;58:443\u20135.", "journal-title": "Br J Hosp Med"}, {"key": "228_CR46", "doi-asserted-by": "crossref", "first-page": "438", "DOI": "10.1016/S0033-3182(99)71210-7", "volume": "40", "author": "LE Goldstein", "year": "1999", "unstructured": "Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40:438\u201343.", "journal-title": "Psychosomatics"}, {"key": "228_CR47", "doi-asserted-by": "crossref", "first-page": "496", "DOI": "10.1002/pbc.25286", "volume": "62", "author": "J Flank", "year": "2016", "unstructured": "Flank J, Thackray J, Nielson D, et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review. Pediatr Blood Cancer. 2016;62:496\u2013501.", "journal-title": "Pediatr Blood Cancer"}, {"key": "228_CR48", "doi-asserted-by": "crossref", "first-page": "791", "DOI": "10.1007/s40264-014-0219-y", "volume": "37", "author": "J Flank", "year": "2014", "unstructured": "Flank J, Sung L, Dvorak C, et al. The safety of olanzapine in young children. A systematic review and meta-analysis. Drug Saf. 2014;37:791\u2013804.", "journal-title": "Drug Saf"}], "container-title": ["Pediatric Drugs"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s40272-017-0228-2.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s40272-017-0228-2/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40272-017-0228-2.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 21]], "date-time": "2019-09-21T14:36:14Z", "timestamp": 1569076574000}, "score": 62.902588, "issued": {"date-parts": [[2017, 4, 21]]}, "references-count": 48, "journal-issue": {"published-print": {"date-parts": [[2017, 6]]}, "issue": "3"}, "alternative-id": ["228"], "URL": "http://dx.doi.org/10.1007/s40272-017-0228-2", "relation": {"cites": []}, "ISSN": ["1174-5878", "1179-2019"], "issn-type": [{"value": "1174-5878", "type": "print"}, {"value": "1179-2019", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T23:27:34Z", "timestamp": 1574465254539}, "reference-count": 0, "publisher": "Informa UK Limited", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["CMR"], "DOI": "10.2147/cmr.s6460", "type": "journal-article", "created": {"date-parts": [[2010, 9, 17]], "date-time": "2010-09-17T05:08:04Z", "timestamp": 1284700084000}, "page": "167", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy"], "prefix": "10.2147", "author": [{"given": "Rudolph", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2009, 12]]}, "container-title": ["Cancer Management and Research"], "language": "en", "deposited": {"date-parts": [[2010, 9, 17]], "date-time": "2010-09-17T05:08:24Z", "timestamp": 1284700104000}, "score": 62.83082, "issued": {"date-parts": [[2009, 12]]}, "references-count": 0, "URL": "http://dx.doi.org/10.2147/cmr.s6460", "ISSN": ["1179-1322"], "issn-type": [{"value": "1179-1322", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T00:04:40Z", "timestamp": 1574813080211}, "reference-count": 0, "publisher": "Informa UK Limited", "license": [{"URL": "http://creativecommons.org/licenses/by-nc/3.0/", "start": {"date-parts": [[2009, 12, 1]], "date-time": "2009-12-01T00:00:00Z", "timestamp": 1259625600000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["CMAR"], "DOI": "10.2147/cmar.s6460", "type": "journal-article", "created": {"date-parts": [[2016, 6, 30]], "date-time": "2016-06-30T00:27:28Z", "timestamp": 1467246448000}, "page": "167-176", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy"], "prefix": "10.2147", "volume": "Volume 1", "author": [{"given": "Rudolph", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2009, 12]]}, "container-title": ["Cancer Management and Research"], "language": "en", "link": [{"URL": "https://www.dovepress.com/getfile.php?fileID=5575", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 10, 30]], "date-time": "2016-10-30T22:06:50Z", "timestamp": 1477865210000}, "score": 62.83082, "issued": {"date-parts": [[2009, 12]]}, "references-count": 0, "URL": "http://dx.doi.org/10.2147/cmar.s6460", "ISSN": ["1179-1322"], "issn-type": [{"value": "1179-1322", "type": "electronic"}]}, {"institution": {"name": "American Psychological Association", "place": ["-"], "acronym": ["APA"]}, "indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T17:03:35Z", "timestamp": 1575219815084}, "reference-count": 0, "publisher": "American Psychological Association (APA)", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2010]]}, "DOI": "10.1037/e548132012-205", "type": "dataset", "created": {"date-parts": [[2013, 5, 6]], "date-time": "2013-05-06T17:11:37Z", "timestamp": 1367860297000}, "source": "Crossref", "is-referenced-by-count": 2, "title": ["Treatment of chemotherapy-induced breakthrough nausea and vomiting"], "prefix": "10.1037", "author": [{"given": "Rudolph", "family": "Navari", "sequence": "first", "affiliation": []}, {"given": "Sarah", "family": "Gray", "sequence": "additional", "affiliation": []}], "member": "15", "container-title": ["PsycEXTRA Dataset"], "deposited": {"date-parts": [[2013, 5, 6]], "date-time": "2013-05-06T17:37:13Z", "timestamp": 1367861833000}, "score": 59.551342, "subtitle": ["(548132012-205)"], "issued": {"date-parts": [[2010]]}, "references-count": 0, "alternative-id": ["548132012-205"], "URL": "http://dx.doi.org/10.1037/e548132012-205"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T16:32:53Z", "timestamp": 1574526773473}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncology Times"], "published-print": {"date-parts": [[2012, 6]]}, "DOI": "10.1097/01.cot.0000415668.40880.4b", "type": "journal-article", "created": {"date-parts": [[2013, 1, 10]], "date-time": "2013-01-10T17:21:45Z", "timestamp": 1357838505000}, "page": "16-19", "source": "Crossref", "is-referenced-by-count": 1, "title": ["How Do I Treat a Patient with Chemotherapy-Induced Nausea and Vomiting?"], "prefix": "10.1097", "volume": "34", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "276", "container-title": ["Oncology Times"], "language": "en", "deposited": {"date-parts": [[2018, 2, 9]], "date-time": "2018-02-09T00:09:52Z", "timestamp": 1518134992000}, "score": 58.783386, "subtitle": [""], "issued": {"date-parts": [[2012, 6]]}, "references-count": 0, "journal-issue": {"issue": "11"}, "URL": "http://dx.doi.org/10.1097/01.cot.0000415668.40880.4b", "ISSN": ["0276-2234"], "issn-type": [{"value": "0276-2234", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T23:31:02Z", "timestamp": 1574724662996}, "reference-count": 45, "publisher": "Hindawi Limited", "license": [{"URL": "http://creativecommons.org/licenses/by/3.0/", "start": {"date-parts": [[2015, 1, 1]], "date-time": "2015-01-01T00:00:00Z", "timestamp": 1420070400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["BioMed Research International"], "published-print": {"date-parts": [[2015]]}, "abstract": "<jats:p>Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30\u201350% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthrough CINV. International guidelines recommend the treatment of breakthrough CINV with an agent from a drug class that was not used in the prophylactic antiemetic regimen and recommend using the breakthrough medication continuously rather than using it on an as needed basis. There have been very few studies on the treatment of breakthrough CINV. A recent double-blind, randomized, phase III study suggested that olanzapine may be an effective agent for the treatment of breakthrough CINV. Refractory CINV occurs when patients develop CINV during subsequent cycles of chemotherapy when antiemetic prophylaxis has not been successful in controlling CINV in earlier cycles. Patients who develop refractory CINV should be considered for a change in their prophylactic antiemetic regimen. If significant anxiety exists, a benzodiazepine may be added to the prophylactic regimen. If a refractory patient is receiving HEC, olanzapine may be added to the prophylactic regimen. If the patient is receiving MEC, olanzapine or an NK-1 receptor antagonist may be added to the prophylactic regimen.</jats:p>", "DOI": "10.1155/2015/595894", "type": "journal-article", "created": {"date-parts": [[2015, 9, 3]], "date-time": "2015-09-03T21:10:34Z", "timestamp": 1441314634000}, "page": "1-6", "source": "Crossref", "is-referenced-by-count": 11, "title": ["Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting"], "prefix": "10.1155", "volume": "2015", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": [{"name": "Indiana University School of Medicine, South Bend, IN 46617, USA"}, {"name": "South Bend Medical Services Corporation, 202 Lincoln Way East, Mishawaka, IN 46544, USA"}]}], "member": "98", "reference": [{"key": "1", "DOI": "10.1200/jco.2006.05.6382", "doi-asserted-by": "publisher"}, {"key": "2", "DOI": "10.1007/s00520-006-0173-z", "doi-asserted-by": "publisher"}, {"key": "3", "DOI": "10.1007/s40265-013-0019-1", "doi-asserted-by": "publisher"}, {"key": "4", "DOI": "10.2217/fon.10.74", "doi-asserted-by": "publisher"}, {"key": "5", "DOI": "10.1517/14656566.2013.799141", "doi-asserted-by": "publisher"}, {"key": "6", "DOI": "10.2165/11203680-000000000-00000", "doi-asserted-by": "publisher"}, {"key": "7", "DOI": "10.1016/j.ejphar.2013.08.048", "doi-asserted-by": "publisher"}, {"key": "8", "DOI": "10.1186/1756-9966-28-131", "doi-asserted-by": "publisher"}, {"key": "9", "DOI": "10.1016/j.suponc.2011.05.002", "doi-asserted-by": "publisher"}, {"key": "10", "DOI": "10.1016/j.cmonc.2011.11.001", "doi-asserted-by": "publisher"}, {"key": "11", "year": "2011"}, {"key": "12", "DOI": "10.1093/annonc/mdq194", "doi-asserted-by": "publisher"}, {"key": "13", "DOI": "10.1200/JCO.2010.34.4614", "doi-asserted-by": "publisher"}, {"key": "14", "year": "2014"}, {"key": "15", "volume": "4", "issue": "4, supplement 1", "first-page": "3S", "year": "2007", "journal-title": "Community Oncology"}, {"key": "16", "DOI": "10.1007/s00520-006-0173-z", "doi-asserted-by": "publisher"}, {"key": "17", "DOI": "10.1002/cncr.22823", "doi-asserted-by": "publisher"}, {"key": "18", "DOI": "10.1002/cncr.20230", "doi-asserted-by": "publisher"}, {"key": "19", "DOI": "10.1002/cncr.11408", "doi-asserted-by": "publisher"}, {"key": "20", "DOI": "10.1200/jco.2003.07.968", "doi-asserted-by": "publisher"}, {"key": "22", "volume": "14", "issue": "8", "first-page": "2242", "year": "1996", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.1996.14.8.2242", "doi-asserted-by": "crossref"}, {"key": "23", "volume": "13", "issue": "5", "first-page": "1242", "year": "1995", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.1995.13.5.1242", "doi-asserted-by": "crossref"}, {"key": "24", "volume": "12", "issue": "11", "first-page": "2439", "year": "1994", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.1994.12.11.2439", "doi-asserted-by": "crossref"}, {"key": "25", "DOI": "10.1056/nejm200005253422102", "doi-asserted-by": "publisher"}, {"key": "26", "DOI": "10.1200/jco.2003.01.095", "doi-asserted-by": "publisher"}, {"key": "27", "DOI": "10.1089/jpm.2011.0058", "doi-asserted-by": "publisher"}, {"key": "28", "volume": "6", "issue": "1", "first-page": "27", "year": "2008", "journal-title": "Journal of Supportive Oncology"}, {"key": "29", "volume": "97", "first-page": "349", "year": "2014", "journal-title": "Journal of the Medical Association of Thailand"}, {"key": "30", "DOI": "10.1007/s00520-012-1710-6", "doi-asserted-by": "publisher"}, {"key": "31", "volume": "23", "first-page": "526", "year": "2002", "journal-title": "Journal of Pain and Symptom Management", "DOI": "10.1016/S0885-3924(02)00391-3", "doi-asserted-by": "crossref"}, {"key": "32", "DOI": "10.1002/(sici)1099-1611(200001/02)9:160;84::aid-pon44062;3.3.co;2-k", "doi-asserted-by": "publisher"}, {"key": "33", "DOI": "10.1089/109662103764978506", "doi-asserted-by": "publisher"}, {"key": "34", "DOI": "10.1016/S0885-3924(03)00143-X", "doi-asserted-by": "publisher"}, {"key": "35", "DOI": "10.1016/0893-133X(94)00129-N", "doi-asserted-by": "publisher"}, {"key": "36", "DOI": "10.1016/S0014-2999(01)01399-1", "doi-asserted-by": "publisher"}, {"key": "37", "DOI": "10.1016/j.neulet.2005.08.062", "doi-asserted-by": "publisher"}, {"key": "38", "DOI": "10.1210/en.2010-0061", "doi-asserted-by": "publisher"}, {"key": "39", "DOI": "10.1007/s00520-004-0755-6", "doi-asserted-by": "publisher"}, {"key": "40", "DOI": "10.1007/s00520-007-0248-5", "doi-asserted-by": "publisher"}, {"key": "41", "DOI": "10.1016/j.jpainsymman.2013.05.003", "doi-asserted-by": "publisher"}, {"key": "42", "DOI": "10.1038/srep04813", "doi-asserted-by": "publisher"}, {"key": "43", "DOI": "10.1007/s00520-014-2138-y", "doi-asserted-by": "publisher"}, {"key": "44", "volume": "5", "issue": "1", "first-page": "24", "year": "2014", "journal-title": "Journal of the Advanced Practitioner in Oncology"}, {"key": "45", "DOI": "10.1007/s00520-009-0680-9", "doi-asserted-by": "publisher"}, {"key": "46", "DOI": "10.1007/s00432-013-1540-z", "doi-asserted-by": "publisher"}], "container-title": ["BioMed Research International"], "language": "en", "link": [{"URL": "http://downloads.hindawi.com/journals/bmri/2015/595894.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://downloads.hindawi.com/journals/bmri/2015/595894.xml", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://downloads.hindawi.com/journals/bmri/2015/595894.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 23]], "date-time": "2017-06-23T18:54:06Z", "timestamp": 1498244046000}, "score": 58.783386, "issued": {"date-parts": [[2015]]}, "references-count": 45, "alternative-id": ["595894", "595894"], "URL": "http://dx.doi.org/10.1155/2015/595894", "relation": {"cites": []}, "ISSN": ["2314-6133", "2314-6141"], "issn-type": [{"value": "2314-6133", "type": "print"}, {"value": "2314-6141", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T07:09:24Z", "timestamp": 1574752164564}, "publisher-location": "Cham", "reference-count": 98, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319216829", "type": "print"}, {"value": "9783319216836", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2015]]}, "DOI": "10.1007/978-3-319-21683-6_37", "type": "book-chapter", "created": {"date-parts": [[2015, 12, 20]], "date-time": "2015-12-20T16:46:01Z", "timestamp": 1450629961000}, "page": "779-804", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Chemotherapy-Induced Nausea and Vomiting: Molecular Mechanisms and Clinical Approaches"], "prefix": "10.1007", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "37_CR1", "doi-asserted-by": "publisher", "first-page": "4472", "DOI": "10.1200/JCO.2006.05.6382", "volume": "24", "author": "B Bloechl-Daum", "year": "2006", "unstructured": "Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "37_CR2", "doi-asserted-by": "publisher", "first-page": "497", "DOI": "10.1007/s00520-006-0173-z", "volume": "15", "author": "L Cohen", "year": "2007", "unstructured": "Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503", "journal-title": "Support Care Cancer"}, {"key": "37_CR3", "doi-asserted-by": "publisher", "first-page": "515", "DOI": "10.2165/00003495-200969050-00002", "volume": "69", "author": "RM Navari", "year": "2009", "unstructured": "Navari RM (2009) Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69:515\u2013533", "journal-title": "Drugs"}, {"key": "37_CR4", "doi-asserted-by": "publisher", "first-page": "51", "DOI": "10.17925/EOH.2013.09.1.51", "volume": "9", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM (2013) A review of the prevention of nausea and vomiting induced by chemotherapy. European Oncol Hematol 9:51\u201355", "journal-title": "European Oncol Hematol"}, {"key": "37_CR5", "doi-asserted-by": "publisher", "first-page": "1074", "DOI": "10.2217/fon.10.74", "volume": "6", "author": "RM Navari", "year": "2010", "unstructured": "Navari RM (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 6:1074\u20131084", "journal-title": "Future Oncol"}, {"key": "37_CR6", "doi-asserted-by": "publisher", "first-page": "1281", "DOI": "10.1517/14656566.2013.799141", "volume": "14", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM (2013) The current status of the use of palonosetron. Expert Opin Pharmacother 14:1281\u20131284", "journal-title": "Expert Opin Pharmacother"}, {"key": "37_CR7", "doi-asserted-by": "publisher", "first-page": "1853", "DOI": "10.2165/11203680-000000000-00000", "volume": "69", "author": "MP Curran", "year": "2009", "unstructured": "Curran MP, Robinson DM (2009) Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 69:1853\u20131858", "journal-title": "Drugs"}, {"key": "37_CR8", "doi-asserted-by": "publisher", "first-page": "1607", "DOI": "10.1517/17425250903451675", "volume": "12", "author": "KK Sankhala", "year": "2009", "unstructured": "Sankhala KK, Pandya DM, Sarantopoulos J et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607\u20131614", "journal-title": "Expert Opin Drug Metab Toxicol"}, {"key": "37_CR9", "doi-asserted-by": "publisher", "first-page": "1285", "DOI": "10.1007/s00520-007-0248-5", "volume": "15", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285\u20131291", "journal-title": "Support Care Cancer"}, {"key": "37_CR10", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/1756-9966-28-131", "volume": "28", "author": "L Tan", "year": "2009", "unstructured": "Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1\u20137", "journal-title": "J Exp Clin Cancer Res"}, {"key": "37_CR11", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1016/j.suponc.2011.05.002", "volume": "9", "author": "RM Navari", "year": "2011", "unstructured": "Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195", "journal-title": "J Support Oncol"}, {"key": "37_CR12", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM (2013) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. European J Pharmacol. doi:\n                  10.1016/jejphar.2013.08.048", "journal-title": "European J Pharmacol", "DOI": "10.1016/jejphar.2013.08.048", "doi-asserted-by": "publisher"}, {"key": "37_CR13", "doi-asserted-by": "publisher", "first-page": "20", "DOI": "10.1016/j.cmonc.2011.11.001", "volume": "9", "author": "RM Navari", "year": "2012", "unstructured": "Navari RM (2012) Treatment of chemotherapy-induced nausea. Community Oncol 9:20\u201326", "journal-title": "Community Oncol"}, {"key": "37_CR14", "author": "RM Stern", "year": "2011", "unstructured": "Stern RM, Koch KL, Andrews PLR (2011) Nausea: mechanisms and management. Oxford University Press, New York", "volume-title": "Nausea: mechanisms and management"}, {"issue": "5", "key": "37_CR15", "doi-asserted-by": "publisher", "first-page": "232", "DOI": "10.1093/annonc/mdq194", "volume": "21", "author": "F Roila", "year": "2010", "unstructured": "Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):232\u2013243", "journal-title": "Ann Oncol"}, {"key": "37_CR16", "doi-asserted-by": "publisher", "first-page": "4189", "DOI": "10.1200/JCO.2010.34.4614", "volume": "29", "author": "E Basch", "year": "2011", "unstructured": "Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198", "journal-title": "J Clin Oncol"}, {"key": "37_CR17", "unstructured": "National Comprehensive Cancer Network (2014) NCCN Clinical practice guidelines in oncology version 1; Antiemetics. \n                  http://nccn.org/professionals.physician_gls/PDF/antiemesis.pdf\n                  \n                . Accessed 9 Dec 2013"}, {"key": "37_CR18", "doi-asserted-by": "crossref", "first-page": "366", "DOI": "10.1016/0168-0102(92)90078-Q", "volume": "14", "author": "T Koga", "year": "1992", "unstructured": "Koga T, Fukuda H (1992) Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema in the pattern generator in the emetic act in dogs. Neurosci Res 14:366\u2013379", "journal-title": "Neurosci Res"}, {"key": "37_CR19", "first-page": "R974", "volume": "267", "author": "BJ Yates", "year": "1994", "unstructured": "Yates BJ, Grelot L, Kerman IA et al (1994) Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol 267:R974\u2013R983", "journal-title": "Am J Physiol"}, {"key": "37_CR20", "unstructured": "Navari RM (2007) Review of updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Community Oncol 4(1 suppl):3S\u201311S"}, {"key": "37_CR21", "doi-asserted-by": "publisher", "first-page": "1655", "DOI": "10.1007/s00520-012-1710-6", "volume": "21", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663", "journal-title": "Support Care Cancer"}, {"key": "37_CR22", "first-page": "550", "volume": "12", "author": "PJ Hesketh", "year": "2004", "unstructured": "Hesketh PJ (2004) New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 12:550\u2013554", "journal-title": "Support Care Cancer"}, {"key": "37_CR23", "first-page": "89", "volume": "1", "author": "RM Navari", "year": "2003", "unstructured": "Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 1:89\u2013103", "journal-title": "J Support Oncol"}, {"key": "37_CR24", "doi-asserted-by": "publisher", "first-page": "1297", "DOI": "10.2165/00003495-200059060-00008", "volume": "59", "author": "K Simpson", "year": "2000", "unstructured": "Simpson K, Spencer CM, McClellan KJ (2000) Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 59:1297\u20131315", "journal-title": "Drugs"}, {"key": "37_CR25", "first-page": "477", "volume": "23", "author": "E Kimura", "year": "1996", "unstructured": "Kimura E, Niimi E, Watanabe A et al (1996) Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 23:477\u20134781", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "37_CR26", "first-page": "1163", "volume": "26", "author": "T Taguchi", "year": "1999", "unstructured": "Taguchi T, Tsukamoto F, Watanabe T et al (1999) Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 26:1163\u20131170", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "37_CR27", "doi-asserted-by": "publisher", "first-page": "163", "DOI": "10.3109/07357900009038248", "volume": "18", "author": "PJ Hesketh", "year": "2000", "unstructured": "Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18:163\u2013173", "journal-title": "Cancer Invest"}, {"key": "37_CR28", "doi-asserted-by": "publisher", "first-page": "1276", "DOI": "10.1345/aph.1C510", "volume": "37", "author": "RM Navari", "year": "2003", "unstructured": "Navari RM, Koeller JM (2003) Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 37:1276\u20131286", "journal-title": "Ann Pharmacother"}, {"issue": "3", "key": "37_CR29", "first-page": "185", "volume": "20", "author": "World Health Organization", "year": "2006", "unstructured": "World Health Organization (2006) Dolasetron mesylate and serious cardiovascular reactions. WHO Drug Inf 20(3):185", "journal-title": "WHO Drug Inf"}, {"key": "37_CR30", "unstructured": "U.S. Food and Drug Administration (2010) FDA drug safety communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). \n                  http://www.fda.gov/Drugs.DrugSafety/usm237081.htm\n                  \n                . Accessed 27 Dec 2010"}, {"key": "37_CR31", "unstructured": "U.S. food and Drug Administration (2013) Dolasetron \n                  http://www.drugs.com/cdi/dolasetron.html\n                  \n                . Accessed 29 Dec 2013"}, {"key": "37_CR32", "unstructured": "U.S. Food and Drug Administration (2013) Ondansetron. \n                  http://www.drugs.com/cdi/ondansetron.html\n                  \n                . Accessed 29 Dec 2013"}, {"issue": "2", "key": "37_CR33", "doi-asserted-by": "publisher", "first-page": "104", "DOI": "10.1007/s00520-004-0700-8", "volume": "13", "author": "F Roila", "year": "2005", "unstructured": "Roila F, Warr D, Clark-Snow R et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):104\u2013108", "journal-title": "Support Care Cancer"}, {"key": "37_CR34", "doi-asserted-by": "publisher", "first-page": "1289", "DOI": "10.1200/JCO.2005.04.022", "volume": "23", "author": "O Geling", "year": "2005", "unstructured": "Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289\u20131294", "journal-title": "J Clin Oncol"}, {"key": "37_CR35", "doi-asserted-by": "publisher", "first-page": "765", "DOI": "10.1016/S1470-2045(05)70325-9", "volume": "6", "author": "JT Hickok", "year": "2005", "unstructured": "Hickok JT, Roscoe JA, Morrow GR et al (2005) 5-HT3 receptor antagonists versus perchlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 6:765\u2013772", "journal-title": "Lancet Oncol"}, {"key": "37_CR36", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1016/S1470-2045(08)70313-9", "volume": "10", "author": "M Saito", "year": "2009", "unstructured": "Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol 10:115\u2013124", "journal-title": "Lancet Oncol"}, {"key": "37_CR37", "doi-asserted-by": "publisher", "first-page": "2822", "DOI": "10.1200/JCO.2005.09.050", "volume": "23", "author": "DG Warr", "year": "2005", "unstructured": "Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822\u20132830", "journal-title": "J Clin Oncol"}, {"key": "37_CR38", "doi-asserted-by": "publisher", "first-page": "354", "DOI": "10.1007/s00520-005-0914-4", "volume": "14", "author": "PJ Hesketh", "year": "2006", "unstructured": "Hesketh PJ, Grunberg SM, Herrstedt J et al (2006) Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354\u2013360", "journal-title": "Support Care Cancer"}, {"key": "37_CR39", "doi-asserted-by": "publisher", "first-page": "1278", "DOI": "10.1016/j.ejca.2005.01.024", "volume": "41", "author": "DG Warr", "year": "2005", "unstructured": "Warr DG, Grunberg SM, Gralla RJ et al (2005) The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer 41:1278\u20131285", "journal-title": "Eur J Cancer"}, {"issue": "8", "key": "37_CR40", "first-page": "403", "volume": "4", "author": "T Grote", "year": "2006", "unstructured": "Grote T, Hajdenberg J, Cartnell A et al (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4(8):403\u2013408", "journal-title": "J Support Oncol"}, {"key": "37_CR41", "doi-asserted-by": "publisher", "first-page": "65", "DOI": "10.1016/j.suponc.2011.06.007", "volume": "10", "author": "L Celio", "year": "2012", "unstructured": "Celio L, Denaro A, Agustoni F et al (2012) Palonosetron plus one day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 10:65\u201371", "journal-title": "J Support Oncol"}, {"key": "37_CR42", "doi-asserted-by": "publisher", "first-page": "1083", "DOI": "10.1093/annonc/mdp584", "volume": "21", "author": "M Aapro", "year": "2010", "unstructured": "Aapro M, Fabi A, Nole F et al (2010) Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for one day with or without dexamethasone on days two and three in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083\u20131088", "journal-title": "Ann Oncol"}, {"key": "37_CR43", "doi-asserted-by": "publisher", "first-page": "601", "DOI": "10.1007/s00520-011-1138-4", "volume": "20", "author": "FM Cruz", "year": "2012", "unstructured": "Cruz FM, de Iracema Gomes Cubero D, Taranto P (2012) Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer 20:601\u2013606", "journal-title": "Support Care Cancer"}, {"key": "37_CR44", "doi-asserted-by": "publisher", "first-page": "533", "DOI": "10.1185/030079907X167525", "volume": "23", "author": "E Meiri", "year": "2007", "unstructured": "Meiri E, Jhangiani H, Vredenburgh JJ et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23:533\u2013543", "journal-title": "Curr Med Res Opin"}, {"key": "37_CR45", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1093/annonc/mdh047", "volume": "15", "author": "P Eisenberg", "year": "2004", "unstructured": "Eisenberg P, MacKintosh FR, Ritch P et al (2004) Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 15:330\u2013337", "journal-title": "Ann Oncol"}, {"key": "37_CR46", "first-page": "193", "volume": "626", "author": "C Rojas", "year": "2010", "unstructured": "Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. J Pharmacol 626:193\u2013199", "journal-title": "J Pharmacol"}, {"key": "37_CR47", "doi-asserted-by": "publisher", "first-page": "1441", "DOI": "10.1093/annonc/mdl137", "volume": "17", "author": "MS Aapro", "year": "2006", "unstructured": "Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441\u20131449", "journal-title": "Ann Oncol"}, {"key": "37_CR48", "doi-asserted-by": "publisher", "first-page": "2473", "DOI": "10.1002/cncr.11817", "volume": "98", "author": "P Eisenberg", "year": "2003", "unstructured": "Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 98:2473\u20132482", "journal-title": "Cancer"}, {"key": "37_CR49", "doi-asserted-by": "publisher", "first-page": "1570", "DOI": "10.1093/annonc/mdg417", "volume": "14", "author": "R Gralla", "year": "2003", "unstructured": "Gralla R, Lichinitser M, Van der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase II trial comparing single dose of palonosetron with ondansetron. Ann Oncol 14:1570\u20131577", "journal-title": "Ann Oncol"}, {"key": "37_CR50", "doi-asserted-by": "publisher", "first-page": "1453", "DOI": "10.1007/s00520-012-1691-5", "volume": "21", "author": "R Boccia", "year": "2013", "unstructured": "Boccia R, Grunberg S, Franco-Gonzales E et al (2013) Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherpay: a phase 3 trial. Support Care Cancer 21:1453\u20131460", "journal-title": "Support Care Cancer"}, {"key": "37_CR51", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1007/s00520-010-0908-8", "volume": "19", "author": "T Borrel", "year": "2011", "unstructured": "Borrel T, Clark O, Clark L et al (2011) Efficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately or highly emetogenic treatment: systematic review and meta- analysis. Support Care Cancer 19:823\u2013832", "journal-title": "Support Care Cancer"}, {"key": "37_CR52", "doi-asserted-by": "publisher", "first-page": "629", "DOI": "10.1517/14656566.2013.771166", "volume": "14", "author": "A Fabi", "year": "2013", "unstructured": "Fabi A, Malaguti P (2013) An update on palonosetron hydrochoride for the treatment radiochemotherapy-induced nausea and vomiting. Expert Opin Pharmacother 14:629\u2013640", "journal-title": "Expert Opin Pharmacother"}, {"issue": "7", "key": "37_CR53", "doi-asserted-by": "publisher", "first-page": "1507", "DOI": "10.1007/s00520-011-1239-0", "volume": "20", "author": "K Aogi", "year": "2012", "unstructured": "Aogi K, Sakai H, Yoshizawa H et al (2012) A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 20(7):1507\u20131514", "journal-title": "Support Care Cancer"}, {"key": "37_CR54", "doi-asserted-by": "publisher", "first-page": "753", "DOI": "10.1111/j.1742-1241.2012.02969.x", "volume": "66", "author": "F Longo", "year": "2012", "unstructured": "Longo F, Mansueto G, Lapadula V et al (2012) Combination of aprepitant, palonosetron, and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Intern J Clin Pract 66:753\u2013757", "journal-title": "Intern J Clin Pract"}, {"key": "37_CR55", "doi-asserted-by": "publisher", "first-page": "2343", "DOI": "10.1007/s00520-011-1348-9", "volume": "20", "author": "C Yavas", "year": "2012", "unstructured": "Yavas C, Dogan U, Yavas G et al (2012) Acute effect of palonmosetron on electrocardiographic parameters in c\u00e1ncer patients: a prospective study. Support Care Cancer 20:2343\u20132347", "journal-title": "Support Care Cancer"}, {"key": "37_CR56", "doi-asserted-by": "publisher", "first-page": "4077", "DOI": "10.1200/JCO.2003.07.968", "volume": "21", "author": "MG Kris", "year": "2003", "unstructured": "Kris MG (2003) Why do we need another antiemetic? J Clin Oncol 21:4077\u20134080", "journal-title": "J Clin Oncol"}, {"key": "37_CR57", "doi-asserted-by": "publisher", "first-page": "533", "DOI": "10.2165/00003495-200060030-00002", "volume": "60", "author": "P Diemunsch", "year": "2000", "unstructured": "Diemunsch P, Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:533\u2013546", "journal-title": "Drugs"}, {"key": "37_CR58", "doi-asserted-by": "publisher", "first-page": "1977", "DOI": "10.1517/13543784.16.12.1977", "volume": "16", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM (2007) Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 16:1977\u20131985", "journal-title": "Expert Opin Investig Drugs"}, {"key": "37_CR59", "doi-asserted-by": "publisher", "first-page": "834", "DOI": "10.1177/0091270007301800", "volume": "47", "author": "KC Lasseter", "year": "2007", "unstructured": "Lasseter KC, Gambale J, Jin B et al (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47:834\u2013840", "journal-title": "J Clin Pharmacol"}, {"issue": "11", "key": "37_CR60", "doi-asserted-by": "publisher", "first-page": "1495", "DOI": "10.1200/JCO.2010.31.7859", "volume": "29", "author": "S Grunberg", "year": "2011", "unstructured": "Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2014EASE. J Clin Oncol 29(11):1495\u20131501", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "37_CR61", "first-page": "774", "volume": "9", "author": "RM Navari", "year": "2008", "unstructured": "Navari RM (2008) Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs 9(7):774\u2013785", "journal-title": "Curr Opin Investig Drugs"}, {"issue": "6", "key": "37_CR62", "doi-asserted-by": "publisher", "first-page": "549", "DOI": "10.1016/S1470-2045(09)70109-3", "volume": "10", "author": "SM Grunberg", "year": "2009", "unstructured": "Grunberg SM, Rolski J, Strausz J et al (2009) Efficacy and safety of casopitant mesylate, a neurokinin-1 receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomized, double-blind, placebo controlled trial. Lancet Oncol 10(6):549\u2013558", "journal-title": "Lancet Oncol"}, {"issue": "32", "key": "37_CR63", "doi-asserted-by": "publisher", "first-page": "5363", "DOI": "10.1200/JCO.2009.21.8511", "volume": "27", "author": "J Herrstedt", "year": "2009", "unstructured": "Herrstedt J, Apornwirat W, Shaharyar A et al (2009) Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27(32):5363\u20135369", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "37_CR64", "doi-asserted-by": "publisher", "first-page": "1471", "DOI": "10.1007/s00520-011-1235-4", "volume": "20", "author": "PJ Hesketh", "year": "2012", "unstructured": "Hesketh PJ, Wright O, Rosati G et al (2012) Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind active-controlled two arm, parallel group study. Support Care Cancer 20(7):1471\u20131478", "journal-title": "Support Care Cancer"}, {"key": "37_CR65", "unstructured": "Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079\u20131089", "DOI": "10.1016/S1470-2045(15)00035-2", "doi-asserted-by": "crossref"}, {"key": "37_CR66", "unstructured": "U.S. National Institutes of Health (2012) Clinical trials, search for studies. \n                  https://clinicaltrials.gov\n                  \n                . Accessed 31 Jul 2012"}, {"key": "37_CR67", "unstructured": "Rossi G, Tilkola SO, Rudengren C et al (2012) A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [abstract no. 9054]. J Clin Oncol 30 suppl"}, {"key": "37_CR68", "unstructured": "Aapro M, Rugo H, Rossi G et al (2014) A randomized phase III study evalu ating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328\u20131333", "DOI": "10.1093/annonc/mdu101", "doi-asserted-by": "crossref"}, {"key": "37_CR69", "unstructured": "Hesketh PJ, Rossi G, Rizzi G et al (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340\u20131346", "DOI": "10.1093/annonc/mdu110", "doi-asserted-by": "crossref"}, {"key": "37_CR70", "doi-asserted-by": "publisher", "first-page": "1011", "DOI": "10.1038/sj.bjc.6603048", "volume": "94", "author": "J Vardy", "year": "1999", "unstructured": "Vardy J, Chiew KS, Gallica J et al (1999) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011\u20131015", "journal-title": "Br J Cancer"}, {"key": "37_CR71", "doi-asserted-by": "publisher", "first-page": "1217", "DOI": "10.1007/s00520-010-0941-7", "volume": "19", "author": "L Celio", "year": "2011", "unstructured": "Celio L, Frustaci S, Denaro A et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi-center, phase III trial. Support Care Cancer 19:1217\u20131225", "journal-title": "Support Care Cancer"}, {"key": "37_CR72", "doi-asserted-by": "publisher", "first-page": "281", "DOI": "10.2165/00003495-199753020-00007", "volume": "53", "author": "B Fulton", "year": "1997", "unstructured": "Fulton B, Goa KL (1997) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281\u2013298", "journal-title": "Drugs"}, {"key": "37_CR73", "doi-asserted-by": "publisher", "first-page": "87", "DOI": "10.1016/0893-133X(94)00129-N", "volume": "14", "author": "FP Bymaster", "year": "1996", "unstructured": "Bymaster FP, Calligaro D, Falcone J et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396", "journal-title": "Neuropsychopharmacology"}, {"key": "37_CR74", "doi-asserted-by": "publisher", "first-page": "341", "DOI": "10.1016/S0014-2999(01)01399-1", "volume": "430", "author": "FP Bymaster", "year": "2001", "unstructured": "Bymaster FP, Falcone JF, Bauzon D et al (2001) Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol 430:341\u2013349", "journal-title": "Eur J Pharmacol"}, {"key": "37_CR75", "first-page": "22", "volume": "62", "author": "DB Allison", "year": "2001", "unstructured": "Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 62:22\u201331", "journal-title": "J Clin Psychiatry"}, {"key": "37_CR76", "first-page": "443", "volume": "58", "author": "AS Hale", "year": "1997", "unstructured": "Hale AS (1997) Olanzapine. Br J Hosp Med 58:443\u2013445", "journal-title": "Br J Hosp Med"}, {"key": "37_CR77", "doi-asserted-by": "publisher", "first-page": "438", "DOI": "10.1016/S0033-3182(99)71210-7", "volume": "40", "author": "LE Goldstein", "year": "1999", "unstructured": "Goldstein LE, Sporn J, Brown S et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438\u2013443", "journal-title": "Psychosomatics"}, {"key": "37_CR78", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1081/CNV-200029066", "volume": "22", "author": "SD Passik", "year": "2004", "unstructured": "Passik SD, Navari RM, Loehrer PJ et al (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest 22:383\u2013388", "journal-title": "Cancer Invest"}, {"key": "37_CR79", "doi-asserted-by": "publisher", "first-page": "529", "DOI": "10.1007/s00520-004-0755-6", "volume": "13", "author": "RM Navari", "year": "2005", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 13:529\u2013534", "journal-title": "Support Care Cancer"}, {"issue": "3", "key": "37_CR80", "doi-asserted-by": "publisher", "first-page": "185", "DOI": "10.1097/AJP.0b013e3181934276", "volume": "25", "author": "G Irving", "year": "2009", "unstructured": "Irving G, Jensen M, Cramer M et al (2009) Efficacy and tolerability of gastric-retentive gabapentin for the treatment of post-herpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 25(3):185\u2013192", "journal-title": "Clin J Pain"}, {"key": "37_CR81", "doi-asserted-by": "publisher", "first-page": "1703", "DOI": "10.1016/S0140-6736(03)13365-X", "volume": "361", "author": "T Guttuso", "year": "2003", "unstructured": "Guttuso T, Roscoe J, Griggs J (2003) Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 361:1703\u20131705", "journal-title": "Lancet"}, {"key": "37_CR82", "unstructured": "Barton DL, Thanarajasingam G, Sloan JA, Diekmann B, Fuloria J, Kottschade LA, Lyss AP, Jaslowski AJ, Mazurczak MA, Blair SC, Terstriep S, Loprinzi CL (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575\u20133583", "DOI": "10.1002/cncr.28892", "doi-asserted-by": "crossref"}, {"key": "37_CR83", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.1126/science.1115740", "volume": "310", "author": "MD Sickle Van", "year": "2005", "unstructured": "Van Sickle MD, Duncan M, Kingsley PJ et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329\u2013332", "journal-title": "Science"}, {"key": "37_CR84", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1016/S0091-3057(01)00531-7", "volume": "69", "author": "NA Darmani", "year": "2001", "unstructured": "Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially supresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav 69:239\u2013249", "journal-title": "Pharmacol Biochem Behav"}, {"issue": "1", "key": "37_CR85", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1517/13543784.17.1.85", "volume": "17", "author": "MP Davis", "year": "2008", "unstructured": "Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17(1):85\u201395", "journal-title": "Expert Opin Investig Drugs"}, {"key": "37_CR86", "doi-asserted-by": "crossref", "first-page": "487", "DOI": "10.6004/jnccn.2012.0048", "volume": "10", "author": "B Todaro", "year": "2012", "unstructured": "Todaro B (2012) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 10:487\u2013492", "journal-title": "J Natl Compr Canc Netw"}, {"key": "37_CR87", "author": "K Bone", "year": "2000", "unstructured": "Bone K, Mills S (2000) Principles and practice of phytotherapy modern health medicine. Elsevier, London", "volume-title": "Principles and practice of phytotherapy modern health medicine"}, {"key": "37_CR88", "doi-asserted-by": "publisher", "first-page": "234", "DOI": "10.1002/pbc.22778", "volume": "56", "author": "AK Pillai", "year": "2011", "unstructured": "Pillai AK, Sharma KK, Gupta YK et al (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving highly emetogenic chemotherapy. Pediatr Blood Cancer 56:234\u2013238", "journal-title": "Pediatr Blood Cancer"}, {"key": "37_CR89", "doi-asserted-by": "publisher", "first-page": "563", "DOI": "10.1007/s00520-008-0528-8", "volume": "17", "author": "SM Zick", "year": "2009", "unstructured": "Zick SM, Ruffin MT, Normolle DP et al (2009) Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 17:563\u2013572", "journal-title": "Support Care Cancer"}, {"issue": "7", "key": "37_CR90", "doi-asserted-by": "publisher", "first-page": "1479", "DOI": "10.1007/s00520-011-1236-3", "volume": "20", "author": "JL Ryan", "year": "2012", "unstructured": "Ryan JL, Heckler C, Roscoe JA et al (2012) Ginger reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 20(7):1479\u20131489", "journal-title": "Support Care Cancer"}, {"key": "37_CR91", "unstructured": "Dabaghzadeh F, Khalili H, Dashi-Khavidaki S (2013) Ginger for the prevention or treatment of drug-induced nausea and vomiting. Curr Clin Pharmacol Epub ahead of print (2014) 9:387\u2013394", "DOI": "10.2174/1574884708666131111205736", "doi-asserted-by": "crossref"}, {"key": "37_CR92", "doi-asserted-by": "publisher", "first-page": "2932", "DOI": "10.1200/JCO.2006.06.9591", "volume": "24", "author": "MG Kris", "year": "2006", "unstructured": "Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932\u20132947", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "37_CR93", "doi-asserted-by": "publisher", "first-page": "423", "DOI": "10.1007/s00520-009-0680-9", "volume": "18", "author": "BL Rapoport", "year": "2010", "unstructured": "Rapoport BL, Jordon K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423\u2013431", "journal-title": "Support Care Cancer"}, {"key": "37_CR94", "doi-asserted-by": "crossref", "first-page": "51", "DOI": "10.6004/jnccn.2007.0007", "volume": "5", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM (2007) Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 5:51\u201359", "journal-title": "J Natl Compr Canc Netw"}, {"key": "37_CR95", "doi-asserted-by": "publisher", "first-page": "1293", "DOI": "10.1007/s00520-007-0255-6", "volume": "15", "author": "LH Einhorn", "year": "2007", "unstructured": "Einhorn LH, Brames ML, Dreicer R et al (2007) Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293\u20131300", "journal-title": "Support Care Cancer"}, {"key": "37_CR96", "doi-asserted-by": "publisher", "first-page": "3998", "DOI": "10.1200/JCO.2011.39.5558", "volume": "30", "author": "C Albany", "year": "2012", "unstructured": "Albany C, Brames ML, Fausel C et al (2012) Randomized, double-blind, placebo-controlled, phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 antagonist plus dexamethasone in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol 30:3998\u20134003", "journal-title": "J Clin Oncol"}, {"key": "37_CR97", "doi-asserted-by": "publisher", "first-page": "2261", "DOI": "10.1002/cncr.20230", "volume": "100", "author": "SM Grunberg", "year": "2004", "unstructured": "Grunberg SM, Deuson R, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer 100:2261\u20132268", "journal-title": "Cancer"}, {"key": "37_CR98", "first-page": "156", "volume": "11", "author": "A Fabi", "year": "2003", "unstructured": "Fabi A, Barduagni M, Lauro S et al (2003) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156\u2013161", "journal-title": "Support Care Cancer"}], "container-title": ["International Manual of Oncology Practice"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-21683-6_37", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T01:00:09Z", "timestamp": 1559350809000}, "score": 58.783386, "issued": {"date-parts": [[2015]]}, "ISBN": ["9783319216829", "9783319216836"], "references-count": 98, "URL": "http://dx.doi.org/10.1007/978-3-319-21683-6_37", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:48:27Z", "timestamp": 1575532107936}, "publisher-location": "Cham", "reference-count": 113, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783030162443", "type": "print"}, {"value": "9783030162450", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2019, 1, 1]], "date-time": "2019-01-01T00:00:00Z", "timestamp": 1546300800000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2019, 1, 1]], "date-time": "2019-01-01T00:00:00Z", "timestamp": 1546300800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "published-print": {"date-parts": [[2019]]}, "DOI": "10.1007/978-3-030-16245-0_46", "type": "book-chapter", "created": {"date-parts": [[2019, 10, 15]], "date-time": "2019-10-15T13:01:34Z", "timestamp": 1571144494000}, "page": "1007-1045", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Chemotherapy Induced Nausea and Vomiting"], "prefix": "10.1007", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2019, 10, 16]]}, "reference": [{"key": "46_CR1", "doi-asserted-by": "publisher", "first-page": "4472", "DOI": "10.1200/JCO.2006.05.6382", "volume": "24", "author": "B Bloechl-Daum", "year": "2006", "unstructured": "Bloechl-Daum B et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478", "journal-title": "J Clin Oncol"}, {"key": "46_CR2", "doi-asserted-by": "publisher", "first-page": "497", "DOI": "10.1007/s00520-006-0173-z", "volume": "15", "author": "L Cohen", "year": "2007", "unstructured": "Cohen L et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497\u2013503", "journal-title": "Support Care Cancer"}, {"key": "46_CR3", "doi-asserted-by": "publisher", "first-page": "1356", "DOI": "10.1056/NEJMra1515442", "volume": "374", "author": "RM Navari", "year": "2016", "unstructured": "Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356\u20131367", "journal-title": "N Engl J Med"}, {"key": "46_CR4", "first-page": "1", "volume": "2", "author": "SM Grunberg", "year": "2004", "unstructured": "Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment\u2014how are we doing? J Support Oncol 2:1\u201310", "journal-title": "J Support Oncol"}, {"key": "46_CR5", "first-page": "171", "volume": "7", "author": "MS Broder", "year": "2014", "unstructured": "Broder MS et al (2014) The impact of 5HT3RA use on cost and utilization in patients with chemotherapy-induced nausea and vomiting: systematic review of the literature. Am Health Drug Benefits 7:171\u2013182", "journal-title": "Am Health Drug Benefits"}, {"key": "46_CR6", "doi-asserted-by": "publisher", "first-page": "249", "DOI": "10.1007/s40265-013-0019-1", "volume": "73", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249\u2013262", "journal-title": "Drugs"}, {"key": "46_CR7", "doi-asserted-by": "publisher", "first-page": "2599", "DOI": "10.1517/14656566.2014.972366", "volume": "15", "author": "RM Navari", "year": "2014", "unstructured": "Navari RM (2014) Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother 15:2599\u20132608", "journal-title": "Expert Opin Pharmacother"}, {"key": "46_CR8", "doi-asserted-by": "publisher", "first-page": "450", "DOI": "10.1634/theoncologist.2014-0229", "volume": "20", "author": "M Aapro", "year": "2015", "unstructured": "Aapro M, Carides A, Rapoport BL (2015) Aprepitant and fosaprepitant: a ten-year review of efficacy and safety. Oncologist 20:450\u2013458", "journal-title": "Oncologist"}, {"key": "46_CR9", "first-page": "155", "volume": "9", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 9:155\u2013161", "journal-title": "Drug Des Devel Ther"}, {"key": "46_CR10", "doi-asserted-by": "publisher", "first-page": "1127", "DOI": "10.1586/14737140.2015.1088787", "volume": "15", "author": "RM Navari", "year": "2015", "unstructured": "Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127\u20131133", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "46_CR11", "doi-asserted-by": "publisher", "first-page": "1285", "DOI": "10.1007/s00520-007-0248-5", "volume": "15", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285\u20131291", "journal-title": "Support Care Cancer"}, {"key": "46_CR12", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/1756-9966-28-131", "volume": "28", "author": "L Tan", "year": "2009", "unstructured": "Tan L et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1\u20137", "journal-title": "J Exp Clin Cancer Res"}, {"key": "46_CR13", "doi-asserted-by": "publisher", "first-page": "188", "DOI": "10.1016/j.suponc.2011.05.002", "volume": "9", "author": "RM Navari", "year": "2011", "unstructured": "Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195", "journal-title": "J Support Oncol"}, {"key": "46_CR14", "doi-asserted-by": "publisher", "first-page": "134", "DOI": "10.1056/NEJMoa1515725", "volume": "375", "author": "RM Navari", "year": "2016", "unstructured": "Navari RM et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142", "journal-title": "N Engl J Med"}, {"key": "46_CR15", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1007/s00520-016-3386-9", "volume": "25", "author": "S Mukhopadhyay", "year": "2017", "unstructured": "Mukhopadhyay S et al (2017) Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer 25:145\u2013154", "journal-title": "Support Care Cancer"}, {"key": "46_CR16", "doi-asserted-by": "publisher", "first-page": "20", "DOI": "10.1016/j.cmonc.2011.11.001", "volume": "9", "author": "RM Navari", "year": "2012", "unstructured": "Navari RM (2012) Treatment of chemotherapy-induced nausea. Commun Oncol 9:20\u201326", "journal-title": "Commun Oncol"}, {"key": "46_CR17", "doi-asserted-by": "publisher", "first-page": "576", "DOI": "10.1634/theoncologist.2014-0438", "volume": "20", "author": "TL Ng", "year": "2015", "unstructured": "Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 20:576\u2013583", "journal-title": "Oncologist"}, {"key": "46_CR18", "author": "RM Stern", "year": "2011", "unstructured": "Stern RM, Koch KL, Andrews PLR (2011) Nausea: mechanisms and management. Oxford University Press, New York", "volume-title": "Nausea: mechanisms and management"}, {"key": "46_CR19", "doi-asserted-by": "publisher", "first-page": "267", "DOI": "10.1007/s00520-016-3324-x", "volume": "25", "author": "A Molassiotis", "year": "2017", "unstructured": "Molassiotis A et al (2017) MASCC/ESMO antiemetic guidelines: introduction to the 2016 guideline update. Support Care Cancer 25:267", "journal-title": "Support Care Cancer"}, {"key": "46_CR20", "doi-asserted-by": "publisher", "first-page": "3240", "DOI": "10.1200/JCO.2017.74.4789", "volume": "35", "author": "PJ Hesketh", "year": "2017", "unstructured": "Hesketh PJ et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240\u20133261", "journal-title": "J Clin Oncol"}, {"key": "46_CR21", "unstructured": "NCCN Clinical Practice Guidelines in Oncology version 2.2017. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: \n                  http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf\n                  \n                . Accessed June, 2017"}, {"key": "46_CR22", "doi-asserted-by": "publisher", "first-page": "366", "DOI": "10.1016/0168-0102(92)90078-Q", "volume": "14", "author": "T Koga", "year": "1992", "unstructured": "Koga T, Fukuda H (1992) Neurons in the nucleus of the solitary tract mediating inputs from Vagal afferents and the area postrema in the pattern generator in the emetic act in dogs. Neurosci Res 14:366\u2013379", "journal-title": "Neurosci Res"}, {"key": "46_CR23", "first-page": "974", "volume": "267", "author": "BJ Yates", "year": "1994", "unstructured": "Yates BJ et al (1994) Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Phys 267:974\u2013983", "journal-title": "Am J Phys"}, {"key": "46_CR24", "doi-asserted-by": "publisher", "first-page": "1297", "DOI": "10.2165/00003495-200059060-00008", "volume": "59", "author": "K Simpson", "year": "2000", "unstructured": "Simpson K, Spencer CM, McClellan KJ (2000) Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 59:1297\u20131315", "journal-title": "Drugs"}, {"key": "46_CR25", "first-page": "477", "volume": "23", "author": "E Kimura", "year": "1996", "unstructured": "Kimura E et al (1996) Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 23:477\u2013481", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "46_CR26", "first-page": "1163", "volume": "26", "author": "T Taguchi", "year": "1999", "unstructured": "Taguchi T et al (1999) Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 26:1163\u20131170", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "46_CR27", "doi-asserted-by": "publisher", "first-page": "163", "DOI": "10.3109/07357900009038248", "volume": "18", "author": "PJ Hesketh", "year": "2000", "unstructured": "Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Investig 18:163\u2013173", "journal-title": "Cancer Investig"}, {"key": "46_CR28", "unstructured": "World Health Organization (2006) Dolasetron mesylate and serious cardiovascular reactions, vol 20. WHO Drug Information, p 185"}, {"key": "46_CR29", "unstructured": "U.S. Food and Drug Information. FDA drug safety communication: abnormal heart rhythms associated with use of anzemet (dolasetron mesylate) [online]. Available from URL: \n                  http://www.fda.gov/Drugs.DrugSafety/usm237081.htm\n                  \n                . Accessed 15 June 2017"}, {"key": "46_CR30", "unstructured": "Ondansetron [online], Available from URL: \n                  www.drugs.com/fda/ondansetron\n                  \n                . Accessed 15 June July 2017"}, {"key": "46_CR31", "first-page": "183", "volume": "6", "author": "JW Mason", "year": "2014", "unstructured": "Mason JW et al (2014) A randomized, placebo-controlled, four-period cross-over definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTC prolongation. Cancer Manag Res 6:183\u2013189", "journal-title": "Cancer Manag Res"}, {"key": "46_CR32", "doi-asserted-by": "publisher", "first-page": "104", "DOI": "10.1007/s00520-004-0700-8", "volume": "13", "author": "F Roila", "year": "2005", "unstructured": "Roila F et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:104\u2013108", "journal-title": "Support Care Cancer"}, {"key": "46_CR33", "doi-asserted-by": "publisher", "first-page": "1289", "DOI": "10.1200/JCO.2005.04.022", "volume": "23", "author": "O Geling", "year": "2005", "unstructured": "Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289\u20131294", "journal-title": "J Clin Oncol"}, {"key": "46_CR34", "doi-asserted-by": "publisher", "first-page": "765", "DOI": "10.1016/S1470-2045(05)70325-9", "volume": "6", "author": "JT Hickok", "year": "2005", "unstructured": "Hickok JT et al (2005) 5-HT3 receptor antagonists versus perchlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 6:765\u2013772", "journal-title": "Lancet Oncol"}, {"key": "46_CR35", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1016/S1470-2045(08)70313-9", "volume": "10", "author": "M Saito", "year": "2009", "unstructured": "Saito M et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol 10:115\u2013124", "journal-title": "Lancet Oncol"}, {"key": "46_CR36", "doi-asserted-by": "publisher", "first-page": "2822", "DOI": "10.1200/JCO.2005.09.050", "volume": "23", "author": "DG Warr", "year": "2005", "unstructured": "Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822\u20132830", "journal-title": "J Clin Oncol"}, {"key": "46_CR37", "doi-asserted-by": "publisher", "first-page": "1609", "DOI": "10.1007/s00520-010-0990-y", "volume": "19", "author": "RV Boccia", "year": "2011", "unstructured": "Boccia RV et al (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19:1609\u20131617", "journal-title": "Support Care Cancer"}, {"key": "46_CR38", "doi-asserted-by": "publisher", "first-page": "723", "DOI": "10.1007/s00520-014-2400-3", "volume": "23", "author": "H Raftopoulos", "year": "2015", "unstructured": "Raftopoulos H et al (2015) Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double blind, noninferiority phase III trial. Support Care Cancer 23:723\u2013732", "journal-title": "Support Care Cancer"}, {"key": "46_CR39", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1093/annonc/mdh047", "volume": "15", "author": "P Eisenberg", "year": "2004", "unstructured": "Eisenberg P et al (2004) Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 15:330\u2013337", "journal-title": "Ann Oncol"}, {"key": "46_CR40", "first-page": "193", "volume": "626", "author": "C Rojas", "year": "2010", "unstructured": "Rojas C et al (2010) Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. J Pharmacol 626:193\u2013199", "journal-title": "J Pharmacol"}, {"key": "46_CR41", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1007/s00520-010-0908-8", "volume": "19", "author": "T Botrel", "year": "2011", "unstructured": "Botrel T et al (2011) Efficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis. Support Care Cancer 19:823\u2013832", "journal-title": "Support Care Cancer"}, {"key": "46_CR42", "doi-asserted-by": "publisher", "first-page": "469", "DOI": "10.1007/s00520-013-1999-9", "volume": "22", "author": "L Schwartzberg", "year": "2014", "unstructured": "Schwartzberg L et al (2014) Pooled analysis of phase III studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 22:469\u2013477", "journal-title": "Support Care Cancer"}, {"key": "46_CR43", "doi-asserted-by": "publisher", "first-page": "1485", "DOI": "10.1007/s00520-014-2175-6", "volume": "22", "author": "M Popovic", "year": "2014", "unstructured": "Popovic M et al (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22:1485\u20131497", "journal-title": "Support Care Cancer"}, {"key": "46_CR44", "doi-asserted-by": "publisher", "first-page": "2343", "DOI": "10.1007/s00520-011-1348-9", "volume": "20", "author": "C Yavas", "year": "2012", "unstructured": "Yavas C et al (2012) Acute effect of palonosetron electrocardiographic parameters in cancer patients; a prospective study. Support Care Cancer 20:2343\u20132347", "journal-title": "Support Care Cancer"}, {"key": "46_CR45", "doi-asserted-by": "publisher", "first-page": "1507", "DOI": "10.1007/s00520-011-1239-0", "volume": "20", "author": "K Aogi", "year": "2012", "unstructured": "Aogi K et al (2012) A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 20:1507\u20131514", "journal-title": "Support Care Cancer"}, {"issue": "5s (suppl)", "key": "46_CR46", "doi-asserted-by": "publisher", "first-page": "abstr 9503", "DOI": "10.1200/jco.2014.32.15_suppl.9503", "volume": "32", "author": "F Roila", "year": "2014", "unstructured": "Roila F et al (2014) Aprepitant versus metoclopramide, both combined with dexamethasone, for the preventing cisplatin-induced delayed emesis: a randomized, double-blind study. J Clin Oncol 32(5s (suppl)):abstr 9503", "journal-title": "J Clin Oncol"}, {"key": "46_CR47", "doi-asserted-by": "publisher", "first-page": "1655", "DOI": "10.1007/s00520-012-1710-6", "volume": "21", "author": "RM Navari", "year": "2013", "unstructured": "Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663", "journal-title": "Support Care Cancer"}, {"key": "46_CR48", "unstructured": "European Medicine Agency Metoclopramide use recommendations, 26 July 2013. \n                  www.ema.europa.eu\n                  \n                . Accessed 15 June 2017"}, {"key": "46_CR49", "doi-asserted-by": "publisher", "first-page": "533", "DOI": "10.2165/00003495-200060030-00002", "volume": "60", "author": "P Diemunsch", "year": "2000", "unstructured": "Diemunsch P, Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:533\u2013546", "journal-title": "Drugs"}, {"key": "46_CR50", "doi-asserted-by": "publisher", "first-page": "1607", "DOI": "10.1517/17425250903451675", "volume": "12", "author": "KK Sankhala", "year": "2009", "unstructured": "Sankhala KK et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607\u20131614", "journal-title": "Expert Opin Drug Metab Toxicol"}, {"key": "46_CR51", "doi-asserted-by": "publisher", "first-page": "354", "DOI": "10.1007/s00520-005-0914-4", "volume": "14", "author": "PJ Hesketh", "year": "2006", "unstructured": "Hesketh PJ et al (2006) Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354\u2013360", "journal-title": "Support Care Cancer"}, {"key": "46_CR52", "doi-asserted-by": "publisher", "first-page": "1278", "DOI": "10.1016/j.ejca.2005.01.024", "volume": "41", "author": "DG Warr", "year": "2005", "unstructured": "Warr DG et al (2005) The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer 41:1278\u20131285", "journal-title": "Eur J Cancer"}, {"key": "46_CR53", "first-page": "403", "volume": "4", "author": "T Grote", "year": "2006", "unstructured": "Grote T et al (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4:403\u2013408", "journal-title": "J Support Oncol"}, {"key": "46_CR54", "doi-asserted-by": "publisher", "first-page": "1977", "DOI": "10.1517/13543784.16.12.1977", "volume": "16", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM (2007) Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 16:1977\u20131985", "journal-title": "Expert Opin Investig Drugs"}, {"key": "46_CR55", "doi-asserted-by": "publisher", "first-page": "1495", "DOI": "10.1200/JCO.2010.31.7859", "volume": "29", "author": "S Grunberg", "year": "2011", "unstructured": "Grunberg S et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2014EASE. J Clin Oncol 29:1495\u20131501", "journal-title": "J Clin Oncol"}, {"key": "46_CR56", "doi-asserted-by": "publisher", "first-page": "1313", "DOI": "10.1007/s00520-013-2089-8", "volume": "22", "author": "AD Leal", "year": "2014", "unstructured": "Leal AD et al (2014) Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer 22:1313\u20131317", "journal-title": "Support Care Cancer"}, {"key": "46_CR57", "unstructured": "Drug interactions of aprepitant [slide presentation]. Available at \n                  http://www.fda.gov/ohrms/dockets/ac/03/slides/3928s1_03_fda-jarugula.ppt\n                  \n                . Accessed 9 June 2017"}, {"key": "46_CR58", "unstructured": "Scientific discussion: this module reflects the initial scientific discussion for the approval of Emend. Available at \n                  http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Scientific_Discussion/human/000527/WC500026534.pdf\n                  \n                . Accessed 9 June 2017"}, {"key": "46_CR59", "doi-asserted-by": "publisher", "first-page": "2316", "DOI": "10.1093/annonc/mdq149", "volume": "21", "author": "MS Aapro", "year": "2010", "unstructured": "Aapro MS, Walko CM (2010) Aprepitant: drug-drug interactions in perspective. Ann Oncol 21:2316\u20132323", "journal-title": "Ann Oncol"}, {"key": "46_CR60", "doi-asserted-by": "publisher", "first-page": "3413", "DOI": "10.1200/JCO.2013.55.0095", "volume": "32", "author": "T Schmitt", "year": "2014", "unstructured": "Schmitt T et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413\u20133420", "journal-title": "J Clin Oncol"}, {"key": "46_CR61", "doi-asserted-by": "publisher", "first-page": "3107", "DOI": "10.1016/j.transproceed.2011.08.010", "volume": "43", "author": "W Pielichowski", "year": "2011", "unstructured": "Pielichowski W et al (2011) A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 43:3107\u20133110", "journal-title": "Transplant Proc"}, {"key": "46_CR62", "doi-asserted-by": "publisher", "first-page": "49", "DOI": "10.1016/j.bbmt.2012.07.019", "volume": "19", "author": "PJ Stiff", "year": "2013", "unstructured": "Stiff PJ et al (2013) Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19:49\u201355", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "46_CR63", "doi-asserted-by": "publisher", "first-page": "31", "DOI": "10.1159/000371523", "volume": "89", "author": "A Svanberg", "year": "2015", "unstructured": "Svanberg A, Bergegard C (2015) Addition of aprepitant to standard antiemetic regimen continued for seven days after chemotherapy for stem cell transplantation provide significant reduction of vomiting. Oncologia 89:31\u201336", "journal-title": "Oncologia"}, {"key": "46_CR64", "doi-asserted-by": "publisher", "first-page": "819", "DOI": "10.1248/bpb.b12-01012", "volume": "36", "author": "M Uchida", "year": "2013", "unstructured": "Uchida M et al (2013) Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36:819\u2013824", "journal-title": "Biol Pharm Bull"}, {"key": "46_CR65", "doi-asserted-by": "publisher", "first-page": "457", "DOI": "10.1007/s12185-014-1538-6", "volume": "99", "author": "M Sakuri", "year": "2014", "unstructured": "Sakuri M et al (2014) Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan\u2013based conditioning for allogeneic hematopoietic stem cell transplantation. Int J Hematol 99:457\u2013462", "journal-title": "Int J Hematol"}, {"key": "46_CR66", "doi-asserted-by": "publisher", "first-page": "2911", "DOI": "10.1007/s00520-014-2248-6", "volume": "22", "author": "T Bechtel", "year": "2014", "unstructured": "Bechtel T et al (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22:2911\u20132916", "journal-title": "Support Care Cancer"}, {"key": "46_CR67", "doi-asserted-by": "publisher", "first-page": "303", "DOI": "10.1007/s00520-016-3449-y", "volume": "25", "author": "LH Einhorn", "year": "2017", "unstructured": "Einhorn LH et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303\u2013308", "journal-title": "Support Care Cancer"}, {"key": "46_CR68", "unstructured": "Ottoboni T et al (2017) Bioequivalence of HTX-019 (aprepitant IV)(Cinvanti) and fosaprepitant in healthy subjects. Hematology/Oncology Pharmacy Association Annual Conference, March 29\u2013April 1, 2017, Anaheim, CA"}, {"key": "46_CR69", "doi-asserted-by": "publisher", "first-page": "86", "DOI": "10.1016/j.peptides.2012.06.010", "volume": "37", "author": "A Rizzi", "year": "2012", "unstructured": "Rizzi A et al (2012) In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist Netupitant. Peptides 37:86\u201397", "journal-title": "Peptides"}, {"key": "46_CR70", "doi-asserted-by": "publisher", "first-page": "97", "DOI": "10.1002/jcph.198", "volume": "54", "author": "T Spinelli", "year": "2014", "unstructured": "Spinelli T, Calcagneli S, Giuliano C (2014) Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol 54:97\u2013108", "journal-title": "J Clin Pharmacol"}, {"key": "46_CR71", "unstructured": "National Cancer Institute Drug Dictionary. Available from \n                  http://www.cancer.gov/drugdictionary\n                  \n                . Accessed 15 June 2017"}, {"key": "46_CR72", "doi-asserted-by": "publisher", "first-page": "1340", "DOI": "10.1093/annonc/mdu110", "volume": "25", "author": "PJ Hesketh", "year": "2014", "unstructured": "Hesketh PJ et al (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340\u20131346", "journal-title": "Ann Oncol"}, {"key": "46_CR73", "doi-asserted-by": "publisher", "first-page": "1328", "DOI": "10.1093/annonc/mdu101", "volume": "25", "author": "M Aapro", "year": "2014", "unstructured": "Aapro M et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328\u20131333", "journal-title": "Ann Oncol"}, {"key": "46_CR74", "doi-asserted-by": "publisher", "first-page": "1333", "DOI": "10.1093/annonc/mdu096", "volume": "25", "author": "RJ Gralla", "year": "2014", "unstructured": "Gralla RJ et al (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333\u20131339", "journal-title": "Ann Oncol"}, {"key": "46_CR75", "unstructured": "FDA News Release. FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy. Available from \n                  http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements\n                  \n                . Accessed 9 June 2017"}, {"key": "46_CR76", "doi-asserted-by": "publisher", "first-page": "95", "DOI": "10.1016/j.pbb.2012.03.021", "volume": "102", "author": "RA Duffy", "year": "2012", "unstructured": "Duffy RA et al (2012) Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK-1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav 102:95\u2013100", "journal-title": "Pharmacol Biochem Behav"}, {"key": "46_CR77", "first-page": "S154", "volume": "21", "author": "A Poma", "year": "2013", "unstructured": "Poma A et al (2013) Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. Support Care Cancer 21:S154. Abstract 441", "journal-title": "Support Care Cancer"}, {"key": "46_CR78", "doi-asserted-by": "publisher", "first-page": "abstr e20690", "DOI": "10.1200/jco.2014.32.15_suppl.e20690", "volume": "32", "author": "A Poma", "year": "2014", "unstructured": "Poma A et al (2014) Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. J Clin Oncol 32:abstr e20690", "journal-title": "J Clin Oncol"}, {"key": "46_CR79", "doi-asserted-by": "publisher", "first-page": "3281", "DOI": "10.1007/s00520-015-2738-1", "volume": "23", "author": "B Rapoport", "year": "2015", "unstructured": "Rapoport B et al (2015) Study of rolapitant, a novel, long acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer 23:3281\u20133288", "journal-title": "Support Care Cancer"}, {"key": "46_CR80", "doi-asserted-by": "publisher", "first-page": "1071", "DOI": "10.1016/S1470-2045(15)00034-0", "volume": "16", "author": "L Schwartzberg", "year": "2015", "unstructured": "Schwartzberg L et al (2015) Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of moderately emetogenic chemotherapy in cancer patients in a randomized phase 3 trial. Lancet Oncol 16:1071\u20131078", "journal-title": "Lancet Oncol"}, {"key": "46_CR81", "doi-asserted-by": "publisher", "first-page": "1079", "DOI": "10.1016/S1470-2045(15)00035-2", "volume": "16", "author": "B Rapoport", "year": "2015", "unstructured": "Rapoport B et al (2015) Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of cisplatin-based highly emetogenic chemotherapy in cancer patients in two randomized phase 3 trials. Lancet Oncol 16:1079\u20131089", "journal-title": "Lancet Oncol"}, {"key": "46_CR82", "doi-asserted-by": "publisher", "first-page": "1280", "DOI": "10.1093/jnci/djs335", "volume": "104", "author": "LV Santos dos", "year": "2012", "unstructured": "dos Santos LV et al (2012) Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 104:1280\u20131292", "journal-title": "J Natl Cancer Inst"}, {"key": "46_CR83", "doi-asserted-by": "publisher", "first-page": "djw217", "DOI": "10.1093/jnci/djw217", "volume": "109", "author": "Y Zhang", "year": "2016", "unstructured": "Zhang Y et al (2016) Neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting: a network meta-analysis. J Natl Cancer Inst 109:djw217. \n                  https://doi.org/10.1093/jnci/djw217", "journal-title": "J Natl Cancer Inst"}, {"key": "46_CR84", "unstructured": "Vardy J et\u00a0al Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 1999, 94:1011\u20131015", "DOI": "10.1038/sj.bjc.6603048", "doi-asserted-by": "crossref"}, {"key": "46_CR85", "doi-asserted-by": "publisher", "first-page": "1217", "DOI": "10.1007/s00520-010-0941-7", "volume": "19", "author": "L Celio", "year": "2011", "unstructured": "Celio L et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi-center, phase III trial. Support Care Cancer 19:1217\u20131225", "journal-title": "Support Care Cancer"}, {"key": "46_CR86", "doi-asserted-by": "publisher", "first-page": "1083", "DOI": "10.1093/annonc/mdp584", "volume": "21", "author": "M Aapro", "year": "2010", "unstructured": "Aapro M et al (2010) Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083\u20131088", "journal-title": "Ann Oncol"}, {"key": "46_CR87", "doi-asserted-by": "publisher", "first-page": "281", "DOI": "10.2165/00003495-199753020-00007", "volume": "53", "author": "B Fulton", "year": "1999", "unstructured": "Fulton B, Goa KL (1999) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281\u2013298", "journal-title": "Drugs"}, {"key": "46_CR88", "doi-asserted-by": "publisher", "first-page": "1325", "DOI": "10.1177/106002809703101110", "volume": "31", "author": "JC Kando", "year": "1997", "unstructured": "Kando JC et al (1997) Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother 31:1325\u20131334", "journal-title": "Ann Pharmacother"}, {"key": "46_CR89", "doi-asserted-by": "publisher", "first-page": "87", "DOI": "10.1016/0893-133X(94)00129-N", "volume": "14", "author": "FP Bymaster", "year": "1996", "unstructured": "Bymaster FP et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396", "journal-title": "Neuropsychopharmacology"}, {"key": "46_CR90", "doi-asserted-by": "publisher", "first-page": "52", "DOI": "10.1192/S0007125000298115", "volume": "174", "author": "CME Stephenson", "year": "1999", "unstructured": "Stephenson CME, Pilowski LS (1999) Psychopharmacology of olanzapine: a review. Br J Psychiatry 174:52\u201358", "journal-title": "Br J Psychiatry"}, {"key": "46_CR91", "doi-asserted-by": "publisher", "first-page": "39", "DOI": "10.3109/15563650.2013.862258", "volume": "52", "author": "AB Petersen", "year": "2014", "unstructured": "Petersen AB et al (2014) Adverse effects associated with high dose therapy in patients admitted to inpatient psychiatric care. Clin Toxicol 52:39\u201343", "journal-title": "Clin Toxicol"}, {"key": "46_CR92", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1081/CNV-200029066", "volume": "22", "author": "S Passik", "year": "2004", "unstructured": "Passik S et al (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Investig 22:383\u2013388", "journal-title": "Cancer Investig"}, {"key": "46_CR93", "doi-asserted-by": "publisher", "first-page": "438", "DOI": "10.1016/S0033-3182(99)71210-7", "volume": "40", "author": "LE Goldstein", "year": "1999", "unstructured": "Goldstein LE et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438\u2013443", "journal-title": "Psychosomatics"}, {"key": "46_CR94", "doi-asserted-by": "publisher", "first-page": "542", "DOI": "10.1016/j.jpainsymman.2013.05.003", "volume": "47", "author": "N Mizukami", "year": "2014", "unstructured": "Mizukami N et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind placebo-controlled study. J Pain Symptom Manag 47:542\u2013550", "journal-title": "J Pain Symptom Manag"}, {"key": "46_CR95", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.12788/jcso.0206", "volume": "14", "author": "MP Davis", "year": "2016", "unstructured": "Davis MP (2016) New therapies for antiemetic prophylaxis for chemotherapy. J Community Support Oncol 14:11\u201320", "journal-title": "J Community Support Oncol"}, {"key": "46_CR96", "doi-asserted-by": "publisher", "first-page": "185", "DOI": "10.1097/AJP.0b013e3181934276", "volume": "25", "author": "G Irving", "year": "2009", "unstructured": "Irving G et al (2009) Efficacy and tolerability of gastric-retentive gabapentin for the treatment of post-herpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 25:185\u2013192", "journal-title": "Clin J Pain"}, {"key": "46_CR97", "doi-asserted-by": "publisher", "first-page": "1703", "DOI": "10.1016/S0140-6736(03)13365-X", "volume": "361", "author": "T Guttuso", "year": "2003", "unstructured": "Guttuso T, Roscoe J, Griggs J (2003) Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 361:1703\u20131705", "journal-title": "Lancet"}, {"key": "46_CR98", "doi-asserted-by": "publisher", "first-page": "601", "DOI": "10.1007/s00520-011-1138-4", "volume": "20", "author": "FM Cruz", "year": "2011", "unstructured": "Cruz FM et al (2011) Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer 20:601\u2013606", "journal-title": "Support Care Cancer"}, {"key": "46_CR99", "doi-asserted-by": "publisher", "first-page": "3575", "DOI": "10.1002/cncr.28892", "volume": "120", "author": "DL Barton", "year": "2014", "unstructured": "Barton DL et al (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575\u20133583", "journal-title": "Cancer"}, {"key": "46_CR100", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.1126/science.1115740", "volume": "310", "author": "MD Sickle Van", "year": "2005", "unstructured": "Van Sickle MD et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329\u2013332", "journal-title": "Science"}, {"key": "46_CR101", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1016/S0091-3057(01)00531-7", "volume": "69", "author": "NA Darmani", "year": "2001", "unstructured": "Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially supresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav 69:239\u2013249", "journal-title": "Pharmacol Biochem Behav"}, {"key": "46_CR102", "doi-asserted-by": "publisher", "first-page": "533", "DOI": "10.1185/030079907X167525", "volume": "23", "author": "E Meiri", "year": "2007", "unstructured": "Meiri E et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23:533\u2013543", "journal-title": "Curr Med Res Opin"}, {"key": "46_CR103", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1517/13543784.17.1.85", "volume": "17", "author": "MP Davis", "year": "2008", "unstructured": "Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17:85\u201395", "journal-title": "Expert Opin Investig Drugs"}, {"key": "46_CR104", "first-page": "49", "volume": "8", "author": "MB May", "year": "2016", "unstructured": "May MB, Grode AE (2016) Dronabinaol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res 8:49\u201355", "journal-title": "Cancer Manag Res"}, {"key": "46_CR105", "doi-asserted-by": "publisher", "first-page": "441", "DOI": "10.1007/s00280-017-3387-5", "volume": "80", "author": "ML Badowski", "year": "2017", "unstructured": "Badowski ML (2017) A review of oral cannabinoids and medical marijuana for the treatment of CINV: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol 80:441\u2013449", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "46_CR106", "doi-asserted-by": "publisher", "first-page": "234", "DOI": "10.1002/pbc.22778", "volume": "56", "author": "AK Pillai", "year": "2011", "unstructured": "Pillai AK et al (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving highly emetogenic chemotherapy. Pediatr Blood Cancer 56:234\u2013238", "journal-title": "Pediatr Blood Cancer"}, {"key": "46_CR107", "doi-asserted-by": "publisher", "first-page": "563", "DOI": "10.1007/s00520-008-0528-8", "volume": "17", "author": "SM Zick", "year": "2009", "unstructured": "Zick SM et al (2009) Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 17:563\u2013572", "journal-title": "Support Care Cancer"}, {"key": "46_CR108", "doi-asserted-by": "publisher", "first-page": "1479", "DOI": "10.1007/s00520-011-1236-3", "volume": "20", "author": "JL Ryan", "year": "2012", "unstructured": "Ryan JL et al (2012) Ginger reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 20:1479\u20131489", "journal-title": "Support Care Cancer"}, {"key": "46_CR109", "doi-asserted-by": "publisher", "first-page": "486", "DOI": "10.1089/acm.2015.0315", "volume": "22", "author": "P Bossi", "year": "2016", "unstructured": "Bossi P et al (2016) Searching for evidence to support the use of ginger in the prevention of chemotherapy-induced nausea and vomiting. J Altern Complement Med 22:486\u2013488", "journal-title": "J Altern Complement Med"}, {"key": "46_CR110", "doi-asserted-by": "publisher", "first-page": "1289", "DOI": "10.1200/JCO.2005.04.022", "volume": "23", "author": "O Geling", "year": "2005", "unstructured": "Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289\u20131294", "journal-title": "J Clin Oncol"}, {"key": "46_CR111", "first-page": "13", "volume": "17", "author": "RM Navari", "year": "2016", "unstructured": "Navari RM (2016) Should behavioral therapy be used as the primary treatment to control anticipatory vomiting? HemeOnc Today 17:13", "journal-title": "HemeOnc Today"}, {"key": "46_CR112", "first-page": "102", "volume": "2", "author": "RM Navari", "year": "2017", "unstructured": "Navari RM (2017) Cancer patients at high risk for chemotherapy-induced nausea and vomiting\u00a0\u2013 prediction assessments/tools. Expert Rev Qual Cancer Care 2:102\u2013108", "journal-title": "Expert Rev Qual Cancer Care"}, {"key": "46_CR113", "doi-asserted-by": "publisher", "first-page": "452", "DOI": "10.1093/annonc/mdx698", "volume": "29", "author": "L Zhang", "year": "2017", "unstructured": "Zhang L et al (2017) A randomized phase 3 study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly Emetogenic chemotherapy (HEC). Ann Oncol 29:452\u2013458. \n                  https://doi.org/10.1093/annonc/mdx698", "journal-title": "Ann Oncol"}], "container-title": ["International Manual of Oncology Practice"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-030-16245-0_46", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 16]], "date-time": "2019-10-16T00:17:50Z", "timestamp": 1571185070000}, "score": 58.783386, "issued": {"date-parts": [[2019]]}, "ISBN": ["9783030162443", "9783030162450"], "references-count": 113, "URL": "http://dx.doi.org/10.1007/978-3-030-16245-0_46", "relation": {"cites": []}, "assertion": [{"value": "16 October 2019", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ChapterHistory", "label": "Chapter History"}}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:15:58Z", "timestamp": 1574522158469}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncology Times UK"], "published-print": {"date-parts": [[2012, 6]]}, "DOI": "10.1097/01.otu.0000415651.19117.a3", "type": "journal-article", "created": {"date-parts": [[2012, 12, 13]], "date-time": "2012-12-13T18:37:50Z", "timestamp": 1355423870000}, "page": "19", "source": "Crossref", "is-referenced-by-count": 0, "title": ["How do I treat \u2026 a patient with chemotherapy-induced nausea and vomiting?"], "prefix": "10.1097", "volume": "9", "author": [{"given": "Rudolph", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "276", "container-title": ["Oncology Times UK"], "language": "en", "deposited": {"date-parts": [[2018, 2, 8]], "date-time": "2018-02-08T18:07:34Z", "timestamp": 1518113254000}, "score": 58.711617, "subtitle": [""], "issued": {"date-parts": [[2012, 6]]}, "references-count": 0, "journal-issue": {"issue": "6"}, "URL": "http://dx.doi.org/10.1097/01.otu.0000415651.19117.a3", "ISSN": ["1742-8009"], "issn-type": [{"value": "1742-8009", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T15:07:43Z", "timestamp": 1574867263726}, "reference-count": 0, "publisher": "Knowledge Enterprise Journals", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["IMRJ"], "published-print": {"date-parts": [[2018]]}, "DOI": "10.18103/imr.v4i4.705", "type": "journal-article", "created": {"date-parts": [[2018, 8, 19]], "date-time": "2018-08-19T22:17:02Z", "timestamp": 1534717022000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Advances in the Prevention of Chemotherapy Induced Nausea and Vomiting"], "prefix": "10.18103", "volume": "4", "author": [{"given": "Rudolph", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "7483", "published-online": {"date-parts": [[2018]]}, "container-title": ["Internal Medicine Review"], "deposited": {"date-parts": [[2018, 8, 19]], "date-time": "2018-08-19T22:17:04Z", "timestamp": 1534717024000}, "score": 58.711617, "issued": {"date-parts": [[2018]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2018]]}, "published-print": {"date-parts": [[2018]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.18103/imr.v4i4.705", "ISSN": ["2470-3524", "2470-3532"], "issn-type": [{"value": "2470-3524", "type": "print"}, {"value": "2470-3532", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T06:21:58Z", "timestamp": 1575181318256}, "reference-count": 84, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2013, 2, 13]], "date-time": "2013-02-13T00:00:00Z", "timestamp": 1360713600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drugs"], "published-print": {"date-parts": [[2013, 3]]}, "DOI": "10.1007/s40265-013-0019-1", "type": "journal-article", "created": {"date-parts": [[2013, 2, 12]], "date-time": "2013-02-12T10:00:19Z", "timestamp": 1360663219000}, "page": "249-262", "source": "Crossref", "is-referenced-by-count": 79, "title": ["Management of Chemotherapy-Induced Nausea and Vomiting"], "prefix": "10.1007", "volume": "73", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2013, 2, 13]]}, "reference": [{"key": "19_CR1", "doi-asserted-by": "crossref", "first-page": "4472", "DOI": "10.1200/JCO.2006.05.6382", "volume": "24", "author": "B Bloechl-Daum", "year": "2006", "unstructured": "Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "19_CR2", "doi-asserted-by": "crossref", "first-page": "497", "DOI": "10.1007/s00520-006-0173-z", "volume": "15", "author": "L Cohen", "year": "2007", "unstructured": "Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5):497\u2013503.", "journal-title": "Support Care Cancer"}, {"key": "19_CR3", "doi-asserted-by": "crossref", "first-page": "515", "DOI": "10.2165/00003495-200969050-00002", "volume": "69", "author": "RM Navari", "year": "2009", "unstructured": "Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs. 2009;69:515\u201333.", "journal-title": "Drugs"}, {"key": "19_CR4", "doi-asserted-by": "crossref", "first-page": "1074", "DOI": "10.2217/fon.10.74", "volume": "6", "author": "RM Navari", "year": "2010", "unstructured": "Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010;6:1074\u201384.", "journal-title": "Future Oncol"}, {"key": "19_CR5", "doi-asserted-by": "crossref", "first-page": "1853", "DOI": "10.2165/11203680-000000000-00000", "volume": "69", "author": "MP Curran", "year": "2009", "unstructured": "Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69:1853\u20138.", "journal-title": "Drugs"}, {"key": "19_CR6", "doi-asserted-by": "crossref", "first-page": "1607", "DOI": "10.1517/17425250903451675", "volume": "12", "author": "KK Sankhala", "year": "2009", "unstructured": "Sankhala KK, Pandya DM, Sarantopoulos J, et al. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol. 2009;12:1607\u201314.", "journal-title": "Expert Opin Drug Metab Toxicol"}, {"key": "19_CR7", "doi-asserted-by": "crossref", "first-page": "1285", "DOI": "10.1007/s00520-007-0248-5", "volume": "15", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2007;15:1285\u201391.", "journal-title": "Support Care Cancer"}, {"key": "19_CR8", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1186/1756-9966-28-1", "volume": "28", "author": "L Tan", "year": "2009", "unstructured": "Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28:1\u20137.", "journal-title": "J Exp Clin Cancer Res"}, {"key": "19_CR9", "doi-asserted-by": "crossref", "first-page": "188", "DOI": "10.1016/j.suponc.2011.05.002", "volume": "9", "author": "RM Navari", "year": "2011", "unstructured": "Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9:188\u201395.", "journal-title": "J Support Oncol"}, {"key": "19_CR10", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.1016/j.cmonc.2011.11.001", "volume": "9", "author": "RM Navari", "year": "2012", "unstructured": "Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol. 2012;9:20\u20136.", "journal-title": "Community Oncol"}, {"key": "19_CR11", "year": "2011", "unstructured": "Stern RM, Koch KL, Andrews PLR, editors. Nausea: mechanisms and management. New York: Oxford University Press; 2011.", "volume-title": "Nausea: mechanisms and management"}, {"issue": "5", "key": "19_CR12", "doi-asserted-by": "crossref", "first-page": "232", "DOI": "10.1093/annonc/mdq194", "volume": "21", "author": "F Roila", "year": "2010", "unstructured": "Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(5):232\u201343.", "journal-title": "Ann Oncol"}, {"key": "19_CR13", "doi-asserted-by": "crossref", "first-page": "4189", "DOI": "10.1200/JCO.2010.34.4614", "volume": "29", "author": "E Basch", "year": "2011", "unstructured": "Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189\u201398.", "journal-title": "J Clin Oncol"}, {"key": "19_CR14", "unstructured": "NCCN Clinical Practice Guidelines in Oncology version 1 2012. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf . Accessed 31 July 2012."}, {"key": "19_CR15", "doi-asserted-by": "crossref", "first-page": "366", "DOI": "10.1016/0168-0102(92)90078-Q", "volume": "14", "author": "T Koga", "year": "1992", "unstructured": "Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema in the pattern generator in the emetic act in dogs. Neurosci Res. 1992;14:366\u201379.", "journal-title": "Neurosci Res"}, {"key": "19_CR16", "first-page": "R974", "volume": "267", "author": "BJ Yates", "year": "1994", "unstructured": "Yates BJ, Grelot L, Kerman IA, et al. Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol. 1994;267:R974\u201383.", "journal-title": "Am J Physiol"}, {"issue": "1 Suppl.", "key": "19_CR17", "first-page": "3S", "volume": "4", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM. Review of updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Community Oncol. 2007;4(1 Suppl.):3S\u201311S.", "journal-title": "Community Oncol"}, {"key": "19_CR18", "first-page": "550", "volume": "12", "author": "PJ Hesketh", "year": "2004", "unstructured": "Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer. 2004;12:550\u20134.", "journal-title": "Support Care Cancer"}, {"key": "19_CR19", "first-page": "89", "volume": "1", "author": "RM Navari", "year": "2003", "unstructured": "Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol. 2003;1:89\u2013103.", "journal-title": "J Support Oncol"}, {"key": "19_CR20", "doi-asserted-by": "crossref", "first-page": "1297", "DOI": "10.2165/00003495-200059060-00008", "volume": "59", "author": "K Simpson", "year": "2000", "unstructured": "Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2000;59:1297\u2013315.", "journal-title": "Drugs"}, {"key": "19_CR21", "first-page": "477", "volume": "23", "author": "E Kimura", "year": "1996", "unstructured": "Kimura E, Niimi E, Watanabe A, et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho. 1996;23:477\u201381.", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "19_CR22", "first-page": "1163", "volume": "26", "author": "T Taguchi", "year": "1999", "unstructured": "Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho. 1999;26:1163\u201370.", "journal-title": "Gan To Kagaku Ryoho"}, {"key": "19_CR23", "doi-asserted-by": "crossref", "first-page": "163", "DOI": "10.3109/07357900009038248", "volume": "18", "author": "PJ Hesketh", "year": "2000", "unstructured": "Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18:163\u201373.", "journal-title": "Cancer Invest"}, {"key": "19_CR24", "doi-asserted-by": "crossref", "first-page": "1276", "DOI": "10.1345/aph.1C510", "volume": "37", "author": "RM Navari", "year": "2003", "unstructured": "Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother. 2003;37:1276\u201386.", "journal-title": "Ann Pharmacother"}, {"key": "19_CR25", "unstructured": "World Health Organization. Dolasetron mesylate and serious cardiovascular reactions. WHO Drug Inf. 2006; 20(3):185."}, {"key": "19_CR26", "unstructured": "U.S. Food and Drug Information. FDA drug safety communication: abnormal heart rhythms associated with use of anzemet (dolasetron mesylate) [online]. Available from URL: http://www.fda.gov/Drugs.DrugSafety/usm237081.htm [Accessed 27 Dec 2010]."}, {"key": "19_CR27", "unstructured": "Dolasetron [online]. http://www.drugs.com/fda/dolasetron . Accessed 27 Jul 2012."}, {"key": "19_CR28", "unstructured": "Ondansetron [online]. http://www.drugs.com/fda/ondansetron . Accessed 27 July 2012."}, {"issue": "2", "key": "19_CR29", "doi-asserted-by": "crossref", "first-page": "104", "DOI": "10.1007/s00520-004-0700-8", "volume": "13", "author": "F Roila", "year": "2005", "unstructured": "Roila F, Warr D, Clark-Snow R, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005;13(2):104\u20138.", "journal-title": "Support Care Cancer"}, {"key": "19_CR30", "doi-asserted-by": "crossref", "first-page": "1289", "DOI": "10.1200/JCO.2005.04.022", "volume": "23", "author": "O Geling", "year": "2005", "unstructured": "Geling O, Eichler H. Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289\u201394.", "journal-title": "J Clin Oncol"}, {"key": "19_CR31", "doi-asserted-by": "crossref", "first-page": "765", "DOI": "10.1016/S1470-2045(05)70325-9", "volume": "6", "author": "JT Hickok", "year": "2005", "unstructured": "Hickok JT, Roscoe JA, Morrow GR, et al. 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol. 2005;6:765\u201372.", "journal-title": "Lancet Oncol"}, {"key": "19_CR32", "doi-asserted-by": "crossref", "first-page": "115", "DOI": "10.1016/S1470-2045(08)70313-9", "volume": "10", "author": "M Saito", "year": "2009", "unstructured": "Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol. 2009;10:115\u201324.", "journal-title": "Lancet Oncol"}, {"key": "19_CR33", "doi-asserted-by": "crossref", "first-page": "2822", "DOI": "10.1200/JCO.2005.09.050", "volume": "23", "author": "DG Warr", "year": "2005", "unstructured": "Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822\u201330.", "journal-title": "J Clin Oncol"}, {"key": "19_CR34", "doi-asserted-by": "crossref", "first-page": "330", "DOI": "10.1093/annonc/mdh047", "volume": "15", "author": "P Eisenberg", "year": "2004", "unstructured": "Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol. 2004;15:330\u20137.", "journal-title": "Ann Oncol"}, {"key": "19_CR35", "first-page": "193", "volume": "626", "author": "C Rojas", "year": "2010", "unstructured": "Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. J Pharmacol. 2010;626:193\u20139.", "journal-title": "J Pharmacol"}, {"key": "19_CR36", "doi-asserted-by": "crossref", "first-page": "1441", "DOI": "10.1093/annonc/mdl137", "volume": "17", "author": "MS Aapro", "year": "2006", "unstructured": "Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441\u20139.", "journal-title": "Ann Oncol"}, {"key": "19_CR37", "doi-asserted-by": "crossref", "first-page": "2473", "DOI": "10.1002/cncr.11817", "volume": "98", "author": "P Eisenberg", "year": "2003", "unstructured": "Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer. 2003;98:2473\u201382.", "journal-title": "Cancer"}, {"key": "19_CR38", "doi-asserted-by": "crossref", "first-page": "1570", "DOI": "10.1093/annonc/mdg417", "volume": "14", "author": "R Gralla", "year": "2003", "unstructured": "Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase II trial comparing single dose of palonosetron with ondansetron. Ann Oncol. 2003;14:1570\u20137.", "journal-title": "Ann Oncol"}, {"issue": "8", "key": "19_CR39", "doi-asserted-by": "crossref", "first-page": "753", "DOI": "10.1111/j.1742-1241.2012.02969.x", "volume": "66", "author": "F Longo", "year": "2012", "unstructured": "Longo F, Mansueto G, Lapadula V, et al. Combination of aprepitant, palonosetron, and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract. 2012;66(8):753\u20137.", "journal-title": "Int J Clin Pract"}, {"issue": "7", "key": "19_CR40", "doi-asserted-by": "crossref", "first-page": "1507", "DOI": "10.1007/s00520-011-1239-0", "volume": "20", "author": "K Aogi", "year": "2012", "unstructured": "Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer. 2012;20(7):1507\u201314.", "journal-title": "Support Care Cancer"}, {"key": "19_CR41", "doi-asserted-by": "crossref", "first-page": "4077", "DOI": "10.1200/JCO.2003.07.968", "volume": "21", "author": "MG Kris", "year": "2003", "unstructured": "Kris MG. Why do we need another antiemetic? J Clin Oncol. 2003;21:4077\u201380.", "journal-title": "J Clin Oncol"}, {"key": "19_CR42", "doi-asserted-by": "crossref", "first-page": "533", "DOI": "10.2165/00003495-200060030-00002", "volume": "60", "author": "P Diemunsch", "year": "2000", "unstructured": "Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60:533\u201346.", "journal-title": "Drugs"}, {"key": "19_CR43", "doi-asserted-by": "crossref", "first-page": "354", "DOI": "10.1007/s00520-005-0914-4", "volume": "14", "author": "PJ Hesketh", "year": "2006", "unstructured": "Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006;14:354\u201360.", "journal-title": "Support Care Cancer"}, {"issue": "9", "key": "19_CR44", "doi-asserted-by": "crossref", "first-page": "1278", "DOI": "10.1016/j.ejca.2005.01.024", "volume": "41", "author": "DG Warr", "year": "2005", "unstructured": "Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9):1278\u201385.", "journal-title": "Eur J Cancer"}, {"issue": "8", "key": "19_CR45", "first-page": "403", "volume": "4", "author": "T Grote", "year": "2006", "unstructured": "Grote T, Hajdenberg J, Cartnell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol. 2006;4(8):403\u20138.", "journal-title": "J Support Oncol"}, {"key": "19_CR46", "doi-asserted-by": "crossref", "first-page": "1977", "DOI": "10.1517/13543784.16.12.1977", "volume": "16", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007;16:1977\u201385.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "19_CR47", "doi-asserted-by": "crossref", "first-page": "834", "DOI": "10.1177/0091270007301800", "volume": "47", "author": "KC Lasseter", "year": "2007", "unstructured": "Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol. 2007;47:834\u201340.", "journal-title": "J Clin Pharmacol"}, {"issue": "11", "key": "19_CR48", "doi-asserted-by": "crossref", "first-page": "1495", "DOI": "10.1200/JCO.2010.31.7859", "volume": "29", "author": "S Grunberg", "year": "2011", "unstructured": "Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2014EASE. J Clin Oncol. 2011;29(11):1495\u2013501.", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "19_CR49", "first-page": "774", "volume": "9", "author": "RM Navari", "year": "2008", "unstructured": "Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs. 2008;9(7):774\u201385.", "journal-title": "Curr Opin Investig Drugs"}, {"issue": "6", "key": "19_CR50", "doi-asserted-by": "crossref", "first-page": "549", "DOI": "10.1016/S1470-2045(09)70109-3", "volume": "10", "author": "SM Grunberg", "year": "2009", "unstructured": "Grunberg SM, Rolski J, Strausz J, et al. Efficacy and safety of casopitant mesylate, a neurokinin-1 receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomized, double-blind, placebo controlled trial. Lancet Oncol. 2009;10(6):549\u201358.", "journal-title": "Lancet Oncol"}, {"issue": "32", "key": "19_CR51", "doi-asserted-by": "crossref", "first-page": "5363", "DOI": "10.1200/JCO.2009.21.8511", "volume": "27", "author": "J Herrstedt", "year": "2009", "unstructured": "Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2009;27(32):5363\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "19_CR52", "doi-asserted-by": "crossref", "first-page": "1471", "DOI": "10.1007/s00520-011-1235-4", "volume": "20", "author": "PJ Hesketh", "year": "2012", "unstructured": "Hesketh PJ, Wright O, Rosati G, et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind active-controlled two arm, parallel group study. Support Care Cancer. 2012;20(7):1471\u20138.", "journal-title": "Support Care Cancer"}, {"key": "19_CR53", "unstructured": "Fein LE, Poma A, Hedley ML. Efficacy and safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy [abstract no. 9077]. J Clin Oncol 2012; 30 Suppl."}, {"key": "19_CR54", "unstructured": "North Central Cancer Treatment Group. Gabapentin in preventing nausea and vomiting in patients receiving chemotherapy [ClinicalTrials.gov identifier NCT00880191]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov . Accessed 25 Jan 2013."}, {"key": "19_CR55", "unstructured": "Rossi G, Tilkola SO, Rudengren C, et al. A positron emission tomography study to assess the degree of neurolinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [abstract no. 9054]. J Clin Oncol 2012; 30 Suppl."}, {"key": "19_CR56", "doi-asserted-by": "crossref", "first-page": "1011", "DOI": "10.1038/sj.bjc.6603048", "volume": "94", "author": "J Vardy", "year": "1999", "unstructured": "Vardy J, Chiew KS, Gallica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 1999;94:1011\u20135.", "journal-title": "Br J Cancer"}, {"key": "19_CR57", "doi-asserted-by": "crossref", "first-page": "1217", "DOI": "10.1007/s00520-010-0941-7", "volume": "19", "author": "L Celio", "year": "2011", "unstructured": "Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi-center, phase III trial. Support Care Cancer. 2011;19:1217\u201325.", "journal-title": "Support Care Cancer"}, {"key": "19_CR58", "doi-asserted-by": "crossref", "first-page": "1083", "DOI": "10.1093/annonc/mdp584", "volume": "21", "author": "M Aapro", "year": "2010", "unstructured": "Aapro M, Fabi A, Nole F, et al. Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1\u00a0day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21:1083\u20138.", "journal-title": "Ann Oncol"}, {"key": "19_CR59", "doi-asserted-by": "crossref", "first-page": "87", "DOI": "10.1016/0893-133X(94)00129-N", "volume": "14", "author": "FP Bymaster", "year": "1996", "unstructured": "Bymaster FP, Calligaro D, Falcone J, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87\u201396.", "journal-title": "Neuropsychopharmacology"}, {"key": "19_CR60", "doi-asserted-by": "crossref", "first-page": "341", "DOI": "10.1016/S0014-2999(01)01399-1", "volume": "430", "author": "FP Bymaster", "year": "2001", "unstructured": "Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol. 2001;430:341\u20139.", "journal-title": "Eur J Pharmacol"}, {"key": "19_CR61", "first-page": "22", "volume": "62", "author": "DB Allison", "year": "2001", "unstructured": "Allison DB, Casey DE. Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry. 2001;62:22\u201331.", "journal-title": "J Clin Psychiatry"}, {"key": "19_CR62", "first-page": "443", "volume": "58", "author": "AS Hale", "year": "1997", "unstructured": "Hale AS. Olanzapine. Br J Hosp Med. 1997;58:443\u20135.", "journal-title": "Br J Hosp Med"}, {"key": "19_CR63", "doi-asserted-by": "crossref", "first-page": "438", "DOI": "10.1016/S0033-3182(99)71210-7", "volume": "40", "author": "LE Goldstein", "year": "1999", "unstructured": "Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40:438\u201343.", "journal-title": "Psychosomatics"}, {"key": "19_CR64", "doi-asserted-by": "crossref", "first-page": "383", "DOI": "10.1081/CNV-200029066", "volume": "22", "author": "SD Passik", "year": "2004", "unstructured": "Passik SD, Navari RM, Loehrer PJ, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest. 2004;22:383\u20138.", "journal-title": "Cancer Invest"}, {"key": "19_CR65", "doi-asserted-by": "crossref", "first-page": "529", "DOI": "10.1007/s00520-004-0755-6", "volume": "13", "author": "RM Navari", "year": "2005", "unstructured": "Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2005;13:529\u201334.", "journal-title": "Support Care Cancer"}, {"key": "19_CR66", "unstructured": "Navari RM, Nagy CK, Gray SE. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013;21: (in press).", "DOI": "10.1007/s00520-012-1710-6", "doi-asserted-by": "crossref"}, {"issue": "3", "key": "19_CR67", "doi-asserted-by": "crossref", "first-page": "185", "DOI": "10.1097/AJP.0b013e3181934276", "volume": "25", "author": "G Irving", "year": "2009", "unstructured": "Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of post-herpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009;25(3):185\u201392.", "journal-title": "Clin J Pain"}, {"key": "19_CR68", "doi-asserted-by": "crossref", "first-page": "1703", "DOI": "10.1016/S0140-6736(03)13365-X", "volume": "361", "author": "T Guttuso", "year": "2003", "unstructured": "Guttuso T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet. 2003;361:1703\u20135.", "journal-title": "Lancet"}, {"key": "19_CR69", "unstructured": "Cruz FM, de Iracema Gomes Cubero D, Taranto P. Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer. 2011; 20: 601\u20136.", "DOI": "10.1007/s00520-011-1138-4", "doi-asserted-by": "crossref"}, {"key": "19_CR70", "doi-asserted-by": "crossref", "first-page": "329", "DOI": "10.1126/science.1115740", "volume": "310", "author": "MD Sickle Van", "year": "2005", "unstructured": "Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329\u201332.", "journal-title": "Science"}, {"key": "19_CR71", "doi-asserted-by": "crossref", "first-page": "239", "DOI": "10.1016/S0091-3057(01)00531-7", "volume": "69", "author": "NA Darmani", "year": "2001", "unstructured": "Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav. 2001;69:239\u201349.", "journal-title": "Pharmacol Biochem Behav"}, {"key": "19_CR72", "doi-asserted-by": "crossref", "first-page": "533", "DOI": "10.1185/030079907X167525", "volume": "23", "author": "E Meiri", "year": "2007", "unstructured": "Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23:533\u201343.", "journal-title": "Curr Med Res Opin"}, {"issue": "1", "key": "19_CR73", "doi-asserted-by": "crossref", "first-page": "85", "DOI": "10.1517/13543784.17.1.85", "volume": "17", "author": "MP Davis", "year": "2008", "unstructured": "Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008;17(1):85\u201395.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "19_CR74", "year": "2000", "unstructured": "Mills S, Bone K, editors. Principles and practice of phytotherapy. Oxford: Churchill Livingstone; 2000.", "volume-title": "Principles and practice of phytotherapy"}, {"key": "19_CR75", "doi-asserted-by": "crossref", "first-page": "234", "DOI": "10.1002/pbc.22778", "volume": "56", "author": "AK Pillai", "year": "2011", "unstructured": "Pillai AK, Sharma KK, Gupta YK, et al. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving highly emetogenic chemotherapy. Pediatric Blood Cancer. 2011;56:234\u20138.", "journal-title": "Pediatric Blood Cancer"}, {"key": "19_CR76", "doi-asserted-by": "crossref", "first-page": "563", "DOI": "10.1007/s00520-008-0528-8", "volume": "17", "author": "SM Zick", "year": "2009", "unstructured": "Zick SM, Ruffin MT, Normolle DP, et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer. 2009;17:563\u201372.", "journal-title": "Support Care Cancer"}, {"issue": "7", "key": "19_CR77", "doi-asserted-by": "crossref", "first-page": "1479", "DOI": "10.1007/s00520-011-1236-3", "volume": "20", "author": "JL Ryan", "year": "2012", "unstructured": "Ryan JL, Heckler C, Roscoe JA, et al. Ginger reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2012;20(7):1479\u201389.", "journal-title": "Support Care Cancer"}, {"key": "19_CR78", "doi-asserted-by": "crossref", "first-page": "2932", "DOI": "10.1200/JCO.2006.06.9591", "volume": "24", "author": "MG Kris", "year": "2006", "unstructured": "Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932\u201347.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "19_CR79", "doi-asserted-by": "crossref", "first-page": "423", "DOI": "10.1007/s00520-009-0680-9", "volume": "18", "author": "BL Rapoport", "year": "2010", "unstructured": "Rapoport BL, Jordon K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423\u201331.", "journal-title": "Support Care Cancer"}, {"key": "19_CR80", "doi-asserted-by": "crossref", "first-page": "51", "DOI": "10.6004/jnccn.2007.0007", "volume": "5", "author": "RM Navari", "year": "2007", "unstructured": "Navari RM. Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw. 2007;5:51\u20139.", "journal-title": "J Natl Compr Canc Netw"}, {"key": "19_CR81", "doi-asserted-by": "crossref", "first-page": "1293", "DOI": "10.1007/s00520-007-0255-6", "volume": "15", "author": "LH Einhorn", "year": "2007", "unstructured": "Einhorn LH, Brames ML, Dreicer R, et al. Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer. 2007;15:1293\u2013300.", "journal-title": "Support Care Cancer"}, {"key": "19_CR82", "doi-asserted-by": "crossref", "first-page": "3998", "DOI": "10.1200/JCO.2011.39.5558", "volume": "30", "author": "C Albany", "year": "2012", "unstructured": "Albany C, Brames ML, Fausel C, et al. Randomized, double-blind, placebo-controlled, phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 antagonist plus dexamethasone in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol. 2012;30:3998\u20134003.", "journal-title": "J Clin Oncol"}, {"key": "19_CR83", "doi-asserted-by": "crossref", "first-page": "2261", "DOI": "10.1002/cncr.20230", "volume": "100", "author": "SM Grunberg", "year": "2004", "unstructured": "Grunberg SM, Deuson R, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer. 2004;100:2261\u20138.", "journal-title": "Cancer"}, {"key": "19_CR84", "first-page": "156", "volume": "11", "author": "A Fabi", "year": "2003", "unstructured": "Fabi A, Barduagni M, Lauro S, et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer. 2003;11:156\u201361.", "journal-title": "Support Care Cancer"}], "container-title": ["Drugs"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s40265-013-0019-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s40265-013-0019-1/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40265-013-0019-1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 2]], "date-time": "2019-06-02T19:41:29Z", "timestamp": 1559504489000}, "score": 57.89897, "subtitle": ["Focus on Newer Agents and New Uses for Older Agents"], "issued": {"date-parts": [[2013, 2, 13]]}, "references-count": 84, "journal-issue": {"published-print": {"date-parts": [[2013, 3]]}, "issue": "3"}, "alternative-id": ["19"], "URL": "http://dx.doi.org/10.1007/s40265-013-0019-1", "relation": {"cites": []}, "ISSN": ["0012-6667", "1179-1950"], "issn-type": [{"value": "0012-6667", "type": "print"}, {"value": "1179-1950", "type": "electronic"}], "subject": ["Pharmacology (medical)"]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T13:57:26Z", "timestamp": 1575295046346}, "reference-count": 42, "publisher": "Elsevier BV", "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Journal of Pharmacology"], "published-print": {"date-parts": [[2014, 1]]}, "DOI": "10.1016/j.ejphar.2013.08.048", "type": "journal-article", "created": {"date-parts": [[2013, 10, 21]], "date-time": "2013-10-21T16:45:07Z", "timestamp": 1382373907000}, "page": "180-186", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 29, "title": ["Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting"], "prefix": "10.1016", "volume": "722", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["European Journal of Pharmacology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0014299913007590?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0014299913007590?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 7, 31]], "date-time": "2019-07-31T01:54:29Z", "timestamp": 1564538069000}, "score": 57.878204, "issued": {"date-parts": [[2014, 1]]}, "references-count": 42, "alternative-id": ["S0014299913007590"], "URL": "http://dx.doi.org/10.1016/j.ejphar.2013.08.048", "ISSN": ["0014-2999"], "issn-type": [{"value": "0014-2999", "type": "print"}], "subject": ["Pharmacology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting", "name": "articletitle", "label": "Article Title"}, {"value": "European Journal of Pharmacology", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ejphar.2013.08.048", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2013 Elsevier B.V. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T23:24:00Z", "timestamp": 1575329040643}, "reference-count": 0, "publisher": "S. Karger AG", "isbn-type": [{"value": "9781910797112", "type": "print"}, {"value": "9781910797143", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016, 4, 18]]}, "DOI": "10.1159/isbn.978-1-910797-14-3", "type": "monograph", "created": {"date-parts": [[2018, 7, 2]], "date-time": "2018-07-02T21:01:37Z", "timestamp": 1530565297000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Fast Facts: Chemotherapy-Induced Nausea and Vomiting"], "prefix": "10.1159", "author": [{"given": "Rudolph M.", "family": "Navari", "sequence": "first", "affiliation": []}, {"given": "Bernardo L.", "family": "Rapoport", "sequence": "additional", "affiliation": []}], "member": "127", "published-online": {"date-parts": [[2016, 4, 18]]}, "deposited": {"date-parts": [[2018, 7, 2]], "date-time": "2018-07-02T21:01:38Z", "timestamp": 1530565298000}, "score": 57.525375, "issued": {"date-parts": [[2016, 4, 18]]}, "ISBN": ["9781910797112", "9781910797143"], "references-count": 0, "URL": "http://dx.doi.org/10.1159/isbn.978-1-910797-14-3"}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}